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1.1 Introduction to microRNAs 
	
MicroRNAs (miRs) are small regulatory RNAs that account for approximately 1% of the 
genome. These are 21-25 nucleotide-long, single-stranded non-coding RNA molecules 
that regulate post-transcriptional gene regulation in eukaryotes by binding to the 3’ 
untranslated region (UTR) of the target mRNA, leading to mRNA cleavage, degradation or 
translational repression (Ambros, 2004; Bartel, 2004; Huntzinger and Izaurralde, 2011). 
 
The maturation of the hairpin transcript of the miRNA can give rise to a 5p strand (present 
in the forward 5’-3’ position) and 3p (complementary to the 5p strand), both of which allow 
the silencing of specific sets of genes through base pairing to a minimal recognition 
sequence (Ambros and Lee, 2004). It is believed that more than 60% of protein-coding 
genes in mammals are controlled by miRs (Esteller, 2011). From the discovery of Lin-4 as 
the first miR to be identified in C.elegans, more than two thousand miRs have been 
discovered up to now (miRBase.org). Each miR has the potential to regulate hundreds of 
mRNAs, and in-turn, a single mRNA can be targeted by many miRs (Friedman et al., 2009; 
Wu et al., 2011)). These small RNAs are now recognized as a major class of gene 
expression regulators with a crucial function in numerous biological processes, such as 
cell development, differentiation, proliferation, stress response and apoptosis (Ameres and 
Zamore, 2013). 
 
1.1.1 MicroRNA biogenesis 
	
The biogenesis of miRs starts with the transcription of independent miR genes or introns 
of protein-coding genes into primary-miRs (Pri-miRs) by RNA polymerase II. The 
transcripts are polyadenylated and capped, a characteristic of RNA polymerase II 
transcription. The Pri-miRs then fold into a hairpin loop, acting as a substrate for two 
members of the RNase III family of enzymes, Drosha and Dicer (Krol et al., 2010). The 5’ 
and 3’ arm of the Pri-miR hairpin loop is then endo-nucleolytically cleaved by the 
Drosha/DGCR8 (DiGeorge critical region 8) complex in mammals, or by Pasha in 
Drosophila melanogaster into precursor miRNA (pre-miR) in the nucleus. After the nuclear 
processing, the pre-miR is recognized and exported into the cytoplasm by Exportin 5. In 
the cytoplasm, a second RNase III enzyme, Dicer, cleaves the loop region and forms a 
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21-25 nucleotide miRNA-miRNA* duplex from pre-miRNA. Dicer interacts with the TRBP 
(Transactivation-response RNA binding protein) and PCAT (Protein Kinase R-activating 
protein) (Ameres and Zamore, 2013; Jonas and Izaurralde, 2015) that facilitates the Dicer-
mediated cleavage of pre-miRNA. After the cleavage, the interaction between Dicer, 
TRBP, and PCAT is dissociated. Subsequently, the double-stranded duplexes are 
separated by helicase, and one of the strands in the duplex with the thermodynamically 
less stable 5’ end will become mature miRNA, also referred to as the guide strand (i.e. 
both the 3p and 5p strand could be functional mature miRNAs). The functional guide 
strand, which is complementary to the target mRNA, is loaded to the Argonaute effector 
complex – also known as the RNA induced silencing complex (RISC) – leading to target 
mRNA degradation, translational repression or mRNA deadenylation. The particular effect 
of an miRNA is based on the degree of complementarity between the miRNA and the 
target mRNA, in combination with the Argonaute proteins in a RISC complex. The other 
strand, also termed the passenger strand, is subsequently degraded (He and Hannon, 
2004; Krol et al., 2010; Winter et al., 2009).Schematic representation of microRNA 
biogenesis is shown in Fig. 1. 
 
 
Figure 1. Schematic representation of microRNA biogenesis (adapted from Ameres 
and Zamore, 2013; He and Hannon, 2004; Krol et al., 2010) 
Introduction   
	
3 
1.2  Lung development 
 
During mouse embryonic lung development, the respiratory system starts to develop from 
embryonic day 9.5 (E9.5) from ventral foregut endoderm. The expression of the 
transcription factor Nkx2.1 (also termed as thyroid transcription factor1 or T/EBP1) in the 
endodermal cells identifies the lung and tracheal progenitors in the foregut endoderm at 
E9 (Morrisey and Hogan, 2010). 
 
At E9.5, two lateral buds from the ventral foregut endoderm evaginate, forming the primary 
bronchial buds of the right and left lungs. In subsequent stages of lung development, these 
primary lung buds undergo continuous branching morphogenesis, leading to the formation 
of one unique left lobe and four right lobes (cranial or rostral, medial, caudal and 
accessory) in the mouse, constituting the complete respiratory tree (Cardoso and Lu, 
2006; Kimura and Deutsch, 2007; Warburton et al., 2010).  
 
1.2.1 Stages of mouse lung development 
 
Lung development can be categorized histologically into four stages. 
 
a) Pseudoglandular stage (mouse E9.5-E16.5; human week 4-17): 
During this stage, the primary lung buds undergo the process of branching 
morphogenesis to form a tree-like network of airways, which later become 
conducting airways. Simultaneously, many of the mesenchymal progenitor cells 
differentiate into smooth muscle cells, endothelial cells, nerve cells, and 
chondrocytes; whereas the epithelial progenitor cells differentiate into basal cells, 
neuroendocrine cells, ciliated cells and secretory cells. 
 
b) Canalicular stage (mouse E16.5-E17.5; human week 17-26):  
In this stage, double-layered blood capillaries are formed. In addition to this, AT1 
and AT2 start to arise from the bipotent alveolar progenitor cells, which first form a 
primitive respiratory epithelium capable of gas exchange. Furthermore, the 
lipofibroblasts that are involved in the production of surfactants start to emerge 
during the canalicular stage (Chao et al., 2015; El Agha and Bellusci, 2014). 
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c) Saccular stage (E17.5-P5; human week 26-36):  
The characteristic feature of this stage is the formation of alveolar sacs (primitive 
alveoli), surfactant production, and expansion of the capillary and lymphatic 
networks. 
 
d) Alveolar stage (mouse P5-P30; human 36 weeks-8yrs):  
During the alveolar stage of lung development, the terminal sacs develop into mature 
alveoli which are characterized by the formation of secondary septae, alveolar 
myofibroblast formation, and microvascular maturation, as well as a massive 
increase in alveolar surface area (El Agha and Bellusci, 2014). The adult mouse lung 
consists of about 2.3 million alveoli with an alveolar surface area of 82 cm2; in an 
adult human, the lung consists of about 300 million alveoli with an alveolar surface 
area of 72 m2 (Chao et al., 2015). 
 
Most of the epithelial and mesenchymal cells start to appear during the pseudoglandular 
stage. Every step during lung development relies on signaling mechanisms as well as 
mutual interaction between the pulmonary epithelium and surrounding endothelium and 
mesenchyme. Any developmental defects during this period can lead to severe impairment 
in lung function in the adult stages (El Agha and Bellusci, 2014; McCulley et al., 2015). 
Fig. 2 summarizes the stages of lung development. 
 





Figure 2. Stages of murine and human lung development  
(adapted from Chao et al., 2015; El Agha and Bellusci, 2014). 
 
1.2.2 Lung mesenchyme 
 
The mesenchyme is an important source of morphogenetic specification and differentiation 
signals. However, it is also the host of surprisingly complex cell lineages that are critical 
for normal lung development and function (Herriges et al., 2014; McCulley et al., 2015). At 
the pseudoglandular stage, the embryonic distal lung bud is composed of three 
morphologically distinguishable layers: the mesothelium (outer layer), the mesenchyme 
(middle layer), and the epithelium (inner layer). The mesenchyme is further grouped into 
two domains, the submesothelial mesenchyme (SMM) and the sub-epithelial 
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mesenchyme (SEM). Wnt2, Gli, Isl1, Ret, Pdgf receptor alpha, Vegfr2, Prox1, Fgf10 and 
Tgfb have been identified as specific markers for different mesenchymal progenitors. The 
mesenchymal compartment consists of a wide variety of cell types, such as airway smooth 
muscle cells, vascular smooth cells, resident mesenchymal cells, lipofibroblasts, 
endothelial cells, chrondocytes, nerve cells, alveolar myofibroblasts, lymphatic cells, and 
others. The mesenchyme is responsible for providing critical signals that control epithelial 
branching morphogenesis as well as epithelial differentiation. It is believed that 
mesenchymal progenitors play an important role not only during lung development but also 
in homeostasis, as well as repair after injury and regeneration (Chao et al., 2015; El Agha 
and Bellusci, 2014). 
 
1.2.3 Lung epithelium 
 
Most of the gas exchange processes take place across the epithelilal cells lining the distal 
lungs. These epithelial cells are derived from multipotent epithelial progenitors, located at 
the tips during pseudoglandular stages in the embryonic lung. These cells are cuboidal 
shaped and express the transcription factors Sox9 and Id2 (Rawlins et al., 2009). As lung 
development progresses, the lineage commitment of epithelial progenitor cells becomes 
restricted to specific cell types (Rock and Hogan, 2011).  
 
During this stage, some distal epithelial progenitor cells start losing Sox9 and Id2 
expression and express the proximal marker Sox2, thus giving rise to proximal bronchiolar 
progenitor cells, whereas the cells retaining both Sox9 and Id2 expression become distal 
alveolar progenitor cells (El Agha and Bellusci, 2014). Distal epithelial progenitors remain 
at the periphery of the lungs until late E17.5 or early E18.5 (Laresgoiti et al., 2016). Various 
pathways like Notch, Wnt, Bmp and Fgf signaling have been shown to be involved in 
epithelial progenitor cell fate determination during lung development (Rock and Hogan, 
2011) 
 
1.2.3.1 Alveolar lung epithelium 
 
The canalicular and saccular stages, extending from E16.5 to E18.5, provide the 
framework for future alveolar development during mouse lung development, and are 
considered a vital stage towards alveologenesis, as the formation of distal airspace 
saccules as well as the differentiation of alveolar epithelial cells occurs. Any interruption in 
this step during lung development can severely damage the lungs of neonates, leading to 
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various serious diseases like bronchopulmonary dysplasia (BPD). Meanwhile, at E17.5, 
an alveolar epithelial differentiation occurs at the bronchio-alveolar junction, which later 
proceeds towards the distal airway tip by E18.5. This leads to the formation of the alveolar 
type I (AT1) and the alveolar type II (AT2) cells, two of the major epithelial cell lineages 
lining the alveolar sacs (Laresgoiti et al., 2016; Wang et al., 2016b). AT1 are flat squamous 
cells that are the primary site for gas exchange and fluid homeostasis. They cover 
approximately 95% of the luminal surface of the alveoli. On the other hand, AT2 cells are 
cuboidal in shape and are usually observed at the corner of the alveoli. AT2 cells are rich 
in lamellar bodies that primarily secrete surfactant protein C (Sftpc), which helps in 
preventing alveolar collapse by decreasing lung surface tension and contributing to the 
host defense mechanism (Rock and Hogan, 2011; Whitsett et al., 2010). 
 
The mechanisms regulating alveolar epithelial cell proliferation and differentiation, as well 
as the advancement of distinct lung progenitor cells towards given mature alveolar cell 
types, are poorly understood (McQualter et al., 2010; Weiss et al., 2008; Zemke et al., 
2009). It has been proposed that AT2 cells can function as progenitors for AT1 cells, thus 
contributing to alveolar repair after lung injury. Recent studies on the lung epithelium using 
cell-specific markers, as well as single-cell transcriptomics during lung development, 
demonstrated that AT1 and AT2 cells are derived from common bipotent progenitor cells 
(Desai et al., 2014; Treutlein et al., 2014), and that weeks after birth, new AT1 and AT2 
cells can be regenerated from rare, self-renewing, long-lived, mature AT2 cells. 
Approximately 1% of the mature AT2 cells show this stem cell capacity. This stem cell 
function is widely activated by AT1 cell injury, EGFR (epidermal growth factor receptor) 
ligand treatment in vitro, and oncogenic Kras (G12D) treatment in vivo, indicating that 
AT2 cells can contribute to lung repair after injury, and function as progenitors for AT1 
cells (Desai et al., 2014). On the contrary, post-natally, AT1 are terminally differentiated 
cells that can be reactivated to proliferate and trans-differentiate to AT2 during lung 
regeneration induced by pneumonectomy (Jain et al., 2015). It is still possible that 
immature AT1 cells also exist in the AT1 lineage postnatally and that these cells have the 
capacity to proliferate and give rise to AT2 cells. Until better markers for pre-AT1 or mature 
AT1 have been characterized, it will be difficult to make conclusions about the exact nature 
of the cells contributing to the repair process. Recently, the role of histone deacetylase 3 
(HDAC3) in the spreading of AT1 and a disruption of lung sacculation was reported. It was 
shown that Hdac3 expressed in alveolar progenitors represses the expression of miR-17-
92, thus allowing proper Tgfb signaling during lung sacculation (Wang et al., 2016b). 
Interestingly, specific deletion of Hdac3 in the developing lung mesenchyme also 
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displayed impairment in AT1 differentiation, correlating with decreased Ctnnb1 signaling 
in the epithelium, whereas rescue of Ctnnb1 signaling in the mutant lung partially rescues 
AT1 cell differentiation defects (Wang et al., 2016a).  
 
A defect in epithelial differentiation and proliferation was also observed in Fgf10 
hypomorphic lungs, which showed impairment in AT2 lineages (Ramasamy et al., 2007). 
Using Fgf10 heterozygous (Fgf10+/-) lungs, Chao and colleagues also demonstrated a 
decrease in the AT2/AT1 cell number ratio, suggesting that Fgf10 represents a crucial 
molecule regulating the differentiation of the bipotent progenitor cells towards the AT2 
lineage (Chao et al., 2017). In addition, Etv5, a downstream target of Fgf10, has been 
recently reported to be important for the maintenance and differentiation of the AT2 cells. 
Conditional deletion of Etv5 expression in differentiated AT2 cells postnatally leads to the 
decrease in the AT2 signature, and an associated increase in the AT1 signature (Zhang 
et al., 2017).   
 
1.3 MicroRNA in lung development and diseases 
 
A complex network of signaling pathways, such as Fgf, Tgfb, Shh and Wnt pathways, are 
involved in lung development processes (Cardoso and Lu, 2006; Warburton et al., 2010). 
MicroRNAs are known to target genes involved in various signaling pathways. Therefore, 
it is likely that microRNAs regulate the multiple signaling mechanisms controlling lung 
development (Bhaskaran et al., 2009). 
 
In recent years, miRNAs have been shown to regulate lung development, homeostasis, 
maintenance and disease (Ornitz and Yin, 2012). Conditional deletion of Dicer, an enzyme 
vital for miR processing, in mouse lung epithelial cells using a Cre/LoxP based approach, 
exhibited defects in epithelial lung branching morphogenesis, revealing the importance of 
miRNAs in epithelial morphogenesis (Harris et al., 2006). Many of the miRs are 
differentially expressed during different phases of lung development (Bhaskaran et al., 
2009; Williams et al., 2007). The expression of the miR-17-92 cluster has been observed 
in the epithelium and mesenchyme during the pseudoglandular stage of lung development 
(Carraro et al., 2009). Targeted deletion of members of the miR-17-92 cluster showed 
early lethality, smaller embryos, and a severe hypoplastic lung phenotype without specific 
defects in branching morphogenesis; in contrast, overexpression results in 
hyperproliferation and inhibition of differentiation of embryonic lung epithelial 
progenitor cells (Lu et al., 2007; Ventura et al., 2008). 
Introduction   
	
9 
During the early stages of lung development, lower expression of miR-127 and miR-351 
were detected. Overexpression of miR-127 at the pseudoglandular stage showed 
decreased branching and enlarged terminal buds. However, both miRs exhibited higher 
expression during the saccular and alveolar stages. The expression pattern of these two 
miRs gradually shifted from the mesenchymal compartment towards  the epithelial 
compartment lining the airways , suggesting their roles in cellular reorganization, 
differentiation of alveolar epithelial cells  and or mesenchymal to epithelial transition 
(Bhaskaran et al., 2009). Growing evidence indicates that miRs are not only involved 
during lung development but also implicated in various pulmonary diseases like COPD, 
asthma, IPF, BPD, cystic fibrosis, and lung cancer. Abnormal expression of certain 
microRNAs in the lungs can contribute to the pathogenesis of lung disease (Angulo et al., 
2012; Johar et al., 2015; Sessa and Hata, 2013). Table 1 summarizes the list of miRs 
involved in various pulmonary diseases. 
 
Table 1. Lists of microRNAs involved in various pulmonary diseases (Compiled from 
Angulo et al., 2012; Johar et al., 2015; Sessa and Hata, 2013) 
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1.4 miR-142: a multifaceted regulator of organogenesis, homeostasis and 
disease 
 
The miR-142 gene is located on chromosome 11 of the mouse genome and on 
chromosome 17 of the human genome. miR-142 encodes for two mature products, derived 
from the same precursor. The microRNA derived from the 3’ arm is termed miR-142-3p 
and the one generated from the 5’ arm is termed miR-142-5p (Fig.3). Both the miRNAs 
are evolutionarily conserved and functionally active. miR-142 is emerging as a critical 
regulator of many biological processes and associated signaling pathways during 
embryonic development, homeostasis and disease. The diverse functions of this miRNA 




Figure 3. miR-142 hairpin loop structure 
 
1.4.1 miR-142 in hematopoiesis 
 
miR-142-3p was first identified in hematopoietic stem cells and is one of the highly  
expressed  microRNAs in hematopoietic cell lineages (Chen et al., 2004), and has been 
shown to regulate the formation and differentiation of hematopoietic stem-progenitor 
lineages and heart development in zebrafish (Fan et al., 2014; Lu et al., 2013; Nishiyama 
et al., 2012). The earliest known regulator of the hematoendothelial lineages was pointed 
out to be miR-142-3p, which acts upstream of the hematopoietic transcription factors Fli-
1, Gata2, Etv5 and Scl (Tal-1). miR-142-3p turns out to be essential for the specification 
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of the hemangioblast precursors of the hematopoietic stem cell lineages, suggesting that 
miRs can be instructive determinants of cell fate during development (Nimmo et al., 2013). 
Using miR-142 general knock out mice, Krammer and colleagues demonstrated that loss 
of miR-142 not only leads to abnormal hematopoietic lineage formation, but also to serious 
immunodeficiency. miR-142 KO mice exhibit hypo-globulinemia and very low immune 
response against soluble antigens and viruses (Kramer et al., 2015). Furthermore, 
independent studies using gene-trapped-based miR-142 KO mice also indicated impaired 
megakaryocyte maturation correlating with abnormal platelet formation and 
thrombocytopenia (Chapnik et al., 2014). We reported similar abnormalities in our classical 
miR-142 knock out mice (Shrestha et al., 2015). Collectively, these findings suggest that 
miR-142 is a master regulator of hematopoiesis. 
 
1.4.2 Role of miR-142 in stem cells		
Stem cell decision to self-renew or differentiate is tightly regulated. Evidence shows that 
miRs play a key role in stem cell homeostasis. It was recently reported that miR-142 is 
differentially expressed in mouse embryonic stem cells (mESCs). The authors reported 
the generation of a reporter cassette made of a bi-directional promoter driving the 
expression of a normalizer (H2B-mCherry) and a miR activity detector (H2B-Citrine), the 
latter containing a miR-142 target sequence in its 3’UTR. This bi-directional reporter is 
made of a back-to-back arrangement of CAG promoters with four CMV enhancers allowing 
efficient expression in mESCs undergoing differentiation and the best signal-to-noise ratio 
for measurement of miR activity in single cells. The precise measurement of the H2B-
Citrine over H2B-mCherry fluorescence is representative of miR-142 activity. Using this 
reporter cassette, the authors confirmed that miR-142-3p is highly expressed in 
undifferentiated cells and downregulated in differentiated cells. In addition, they also 
demonstrated  that  the expressionof miR-142 locks the mESCs in an undifferentiated 
state. Deletion of miR-142 in embryonic stem cells leads to the differentiation of these cells 
along the neuroectoderm, mesoderm and endoderm fate with a complete absence of Oct4 
expression, which is a pluripotency marker. By contrast, overexpression of miR-142 
prevented the differentiation of the ES cells and maintained Oct4 expression. A double 
negative feedback loop between KRas/ERK and miR-142 levels has been suggested as a 
mechanism of action. Low level of miR-142 induces KRas and Erk phosphorylation thus 
initiating differentiation and vice versa (Sladitschek and Neveu, 2015). This suggests a 
novel mechanism by which miR-142 can play an important role in maintaining stem cell 
pluripotency during organogenesis. 
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1.4.3 Role of miR-142 in cardiomyocyte hypertrophy 
 
Postnatally, adaptive cardiomyocyte hypertrophy is a normal mechanism allowing an 
increase in heart size without requiring cell proliferation. However, in diseases such as 
hypertension, aortic valvular stenosis leads to an increase in cardiac workload, and a 
maladaptive cardiomyocyte hypertrophy has been observed.  Prolonged maladaptive 
hypertrophy is likely to lead to heart failure. The molecular mechanisms controlling 
adaptive versus maladaptive cardiac growth are therefore critical from a therapeutic point 
of view. Interestingly, an inverse relationship has been observed between the levels of 
miR-142 and cardiac hypertrophy. miR-142-5p and miR-142-3p were found to be down-
regulated during cardiac hypertrophy, by mechanisms requiring Ep300, a transcription 
factor involved in cardiac growth and MAP kinase activity. Ep300 is a direct target of miR-
142 (Sharma et al., 2012). The levels of Ep300 are sharply increased during hemodynamic 
stress, heart failure, and cardiac hypertrophy. However, a small increment or decrement 
in the level of Ep300 can drastically influence the extent of adaptive cardiac hypertrophy 
and risk of heart failure (Morimoto et al., 2008; Wei et al., 2008). In addition, miR-142 can 
inhibit the cytokine signaling mechanism by targeting the cytokine receptor gp130, a critical 
receptor required for cardiac muscle cell survival. Down-regulation of miR-142 in mice 
leads to increase in Ep300 and gp130, ultimately increasing the rate of cytokine-mediated 
survival signals, reduction in apoptosis and heart failure during postnatal growth of the 
heart. These results suggest that miR-142 is essential for the successful adaptation and 
survival of the heart due to changing hemodynamic demand in vivo (Sharma et al., 2012). 
 
1.4.4 miR-142 as a biomarker for the diseased state 
 
miRs have emerged as biomarkers of various diseases such as cancer and heart 
disorders. In addition, miRs can represent potential gene-specific therapeutic targets in 
disease models (Schulte and Zeller, 2015). Circulating miR-142-3p in serum or plasma 
was found to be associated with a high risk of cancer recurrence in patients with early-
stage lung adenocarcinoma (Kaduthanam et al., 2013). Another study showed that miR-
142-3p was involved in the progression of esophageal squamous cell carcinoma (ESCC) 
and identified this miR as a potential prognostic biomarker for ESCC (Lin et al., 2012). 
Meanwhile, miR-142-5p, along with miR-486-5p, have been suggested as potential 
biomarkers for early detection of chronic antibody-mediated rejection in kidney 
transplantation (Iwasaki et al., 2016). Furthermore, the level of miR-142-3p and -5p are 
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significantly decreased in acute and chronic heart failure, respectively, indicating that 
these two miRs may act as specific biomarkers for heart failure (Vegter et al., 2016). 
 
1.4.5 miR-142 and immune tolerance 
 
Autoimmune diseases are disorders of the immune system where the body’s own immune 
response targets healthy cells for destruction due to decreased immunologic tolerance to 
auto reactive immune cells. Recent studies have shown that aberrant miR expression 
often correlates with the onset and prognosis of autoimmune disorders. This observation 
suggests that dysregulation in miR expression can elicit a serious effect on immune 
response and immune tolerance (Chen et al., 2013). 
 
Developing a drug-free immune tolerance therapy or the successful use of a very low 
number of immunosuppressive drugs can make a huge impact in the field of human organ 
transplantation. A high level of miR-142-3p was observed in the peripheral blood 
mononuclear cells from immune-tolerant patients who underwent a kidney transplant. 
Further work suggested that a negative feedback loop involving Tgfb signaling and miR-
142-3p in peripheral blood mononuclear cells might be responsible for contributing to 
immune tolerance (Danger et al., 2012). 
 
In addition, mice treated with a miR-142-regulated lentiviral vector encoding GFP and 
subsequently vaccinated with GFP are tolerant to the development of antibodies against 
GFP and display increased GFP-specific regulatory T cells. In control animals treated with 
the non-related miR-122a, a robust immune response to GFP is observed after 
vaccination. It was therefore proposed that miR-142 can be used to induce immunologic 
tolerance to a gene-encoded antigen and could be used as a tool for gene therapy in 
patients with autoimmune disorders or patients requiring organ transplantation (Annoni et 
al., 2009).  
 
1.4.6 miR-142 in cancer 
 
Cancer studies suggest that miRs are useful biomarkers of cancer development and tumor 
stages. Recent evidence has shown that miR mutations or mis-expressions correlate with 
various human cancer, indicating that miRs can function as tumor suppressors and/or 
oncogenes depending on the cellular function of their targets (Calin and Croce, 2006). The 
expression level of miR-142-3p in cervical cancer epithelial cells was significantly lower 
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than in healthy cervical epithelial cells, indicating a regulatory impact of miR-142-3p in 
cervical cancer. miR-142-3p inhibits cell proliferation and invasion via targeting Frizzled 7 
(Fzd7) receptor in Hela and SiHa cells. Fzd7 overexpression was able to reverse the effect 
induced by miR-142-3p. miR-142-3p is, therefore, a potential therapeutic target for cervical 
cancer (Deng et al., 2015). Similarly, miR-142-3p has been involved in inhibiting tumor 
progression and invasion in hepatocellular carcinoma cells (Tsang et al., 2015; Wu et al., 
2011). Furthermore, in acute myeloid leukemia miR-142-3p has been found to be 
downregulated. Increasing the expression of miR-142-3p by promoting myeloid 
differentiation could therefore be a potential strategy for AML treatment (Wang et al., 
2012). 
 
Paradoxically, high levels of miR-142-5p expression correlate with cancer progression 
through regulating the Tgfb-signaling pathway. In particular, miR-142-5p targets Smad3, 
thereby suppressing Tgfb-induced growth inhibition in cancer cells. Overexpression of 
miR-142-5p leads to increased tumor cell proliferation and decreased apoptosis, while 
silencing of miR-142-5p leads to the opposite effects (Ma et al., 2016). Similarly, miR-142-
3p can repress Tgfb-induced growth inhibition by targeting the Tgfbr1 receptor in non-small 
cell lung carcinoma cell lines (Lei et al., 2014). 
 
A study performed by Isobe and colleagues demonstrated that miR-142-3p triggers the 
progression of tumors in human breast stem cells by targeting Adenomatous Polyposis 
Coli (APC). Loss of APC expression activates the canonical WNT/CTNNB1 signaling 
pathway leading to excessive cell growth in breast tissue (Isobe et al., 2014). Furthermore, 
studies in glioblastoma tumorigenesis showed that Interleukin 6 inhibits miR-142-3p 
expression via the increased methylation of the miR-142-3p promoter. In addition, high 
mobility group AT-hook2 (HMGA2), a target of miR-142-3p, is upregulated, leading to 
increased SOX2 expression, a transcription factor required to maintain stem cell-like 
properties in glioblastoma cells and associated with glioblastoma malignancy (Chiou et al., 
2013). 	
1.4.7 Role of miR-142 during lung development and disease		
Increased levels of miR-142-3p in serum has been observed in patients with lung 
adenocarcinoma (Kaduthanam et al., 2013). miR-142-3p has  also been shown to be 
upregulated in human breast cancer stem cells, which leads to the activation of the 
canonical Wnt signaling pathway by reducing the level of APC, thus resulting in enhanced 
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tumorigenicity (Isobe et al., 2014). Increased levels of miR-142-3p were observed in the 
sputum of patients suffering from severe inflammatory asthma (Maes et al., 2016). In the 
transgenic mouse model of lung cancer, the expression of miR-142-5p is down-regulated 
and over-expression of this microRNA markedly reduced proliferation in murine cancer cell 
lines (Liu et al., 2009). However, a study by Kee et al. observed that miR-142-5p enhances 
the vascular smooth muscle cell proliferation by down-regulating the B cell translocation 
gene (Kee et al., 2013).  
 
During early embryonic lung development, miR-142-3p is highly expressed in the lung 
mesenchyme. Such restricted expression patterns suggest that miR-142-3p could play 
functions in controlling cell lineage formation in the lung mesenchyme. Using an in vitro 
embryonic mouse lung organ culture treated with morpholino (which inhibits microRNA 
expression and function) specific to miR-142-3p, a decreased proliferation of 
mesenchymal cells, as well as a premature differentiation of smooth muscle progenitor 
cells, was observed. Further evidence has shown that miR-142-3p controls Wnt/Ctnnb1 
(b-catenin) signaling in the mesenchyme by targeting Adenomatous polyposis coli (APC). 
APC is a negative regulator of Wnt/Ctnnb1 (b-catenin) signaling, which controls both cell 
proliferation and differentiation. In combination with Axin and GSK3b, APC induces 
ubiquitination and degradation of Ctnnb1.This results in decreased Wnt signaling and 
hence affects cell proliferation and differentiation. Therefore, miR-142-3p positively 
regulates Wnt/Ctnnb1 signaling by targeting APC for its destruction (Carraro et al., 2014). 
On the other hand, Ep300 is a target of miR-142-5p.	A mutual inhibitory loop between 
Ep300 and miR-142-5p has also been described, and under mechanical stress, Ep300 
accumulates in the cardiac cells, which results in the down-regulation of miR-142-5p. This 
loss of miR-142-5p expression activates genes required for myocyte survival and function 
(Sharma et al., 2012). Ep300 is a positive regulator of b-catenin that synergistically 
activates b-catenin/TCF transcription (Sun et al., 2000). In conclusion, miR-142 seems to 













Figure 4. Regulation of Wnt signaling by miR-142: miR-142-3p regulates Wnt signaling 
by targeting APC whereas miR-142-5p regulates via targeting Ep300. 





In order to determine, in vivo, the multiple roles played by miR-142 in organogenesis, 
homeostasis and disease, we planned to use a miR-142 classical knock out mouse line.  
 
miR-142-3p targets Apc, leading to its destruction (Carraro et al., 2014). This results in the 
up-regulation of Wnt signaling, whereas miR-142-5p targets Ep300 (Sharma et al., 2012), 
which leads to down-regulation of Wnt signaling. One being a negative regulator and the 
other being a positive regulator, we hypothesize that miR-142 is a key regulator of  Wnt 
signaling. Therefore, it would be interesting to understand how miR-142 regulates the Wnt 
signaling pathway during lung development and disease via Apc and Ep300. 
 
It has also been observed that miR-142-3p and miR-142-5p are up-regulated in the 
bronchioalveolar epithelial cells (BASCs) (Qian et al., 2008), which are suggested as a 
specific epithelial/stem progenitor cell pool in the lungs of mice and humans, that maintains 
brionchiolar epithelial (Clara) cells and Alveolar cells (AT1 and AT2) of the distal lung 
(Kotton and Morrisey, 2014). Proper formation of epithelial lineages is important for overall 
lung function. Hence, we further propose that miR-142 regulates the formation and 
differentiation of epithelial progenitor cells. 
 
Aims: 
1. To understand the function of miR-142 during in vivo lung development. 
2. To investigate how miR-142 regulates the Wnt signaling pathway during lung 
development and disease via Apc and Ep300. 
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3 Materials and Methods 
 
3.1 Study approval 
Animal experiments were approved by the Federal Authorities of Animal Research of the 
Regierungspräsidium Giessen, Hessen, Germany with approved protocol numbers 
405_M, 423_M, 610_M, 613_M, G 47/2017 and G54/2017. 
 
3.2 Generation and genotyping of mice 
 
3.2.1 miR-142 KO mouse line establishment 
 
The miR-142 KO mutant mouse line was established at the MCI/ICS (Institut Clinique de 
la Souris, iCS, Infrastructure Nationale PHENOMIN, 1 rue Laurent Fries, 67404 IIIkirch, 
France). A MCI proprietary vector containing a floxed neomycin resistance cassette and 
Protamine-Cre cassette was used. The use of protamine-Cre cassette in the construction 
vector offers an efficient solution for the auto-excision of the floxed region in the male 
germ line of mice.  In parallel, a 3.3kb fragment (corresponding to the 5’ homology arm) 
and 2.6kb fragment (corresponding to the 3’ homology arms) were amplified by PCR and 
sub-cloned in MCI proprietary vector to generate the final targeting construct. The 
linearized construct was electroporated in C57BL/6N mouse embryonic stem (ES) cells. 
After selection, targeted clones were identified by PCR using external primers and further 
confirmed by Southern blot with 3’ external probe. Two positive recombinant ES clones 
were injected into Balb/CN blastocysts, and resulting male chimeras were crossed with 
wild type females. The genotype of mice with germ line transmission was confirmed using 
the primers described below.  
 
3.2.2 Genotyping of miR-142 KO mice 
 
miR-142 heterozygous and KO mutant mice were identified by performing PCR on tail 
genomic DNA with primers called P1, P2, P3 and P4. The P2/P3 primers couple allows 
detecting the miR-142 wild type allele (174 bp). The P1/P4 primers couple allows detecting 
the presence of the LoxP cassette (105 bp). The P1/P3 primers couple allows detecting 
the deletion of the endogenous miR-142 gene (254 bp).  
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(P1) forward: GAA GAA CGA GAT CAG CAG CCT CTG TTC C; (P2) forward: ACG CTA 
GCA CAG TGT GTG CCC A; (P3) reverse: ACC CAT ATG ATA CAC CAG CCA CGT C; 
(P4) reverse:GAA GTT ATA CTA GAG CGG CCG TTC AC. 
The PCR program consists of a denaturation step at 95°C for 4 min, followed by 34 cycles 
of denaturation (94°C for 30 secs), annealing (62°C for 30 secs) and extension steps 
(72°C for 60 secs). The program ends with a completion step at 72°C for 420 secs. Each 
PCR tube contains 2.6 U of Taq polymerase in 5µl of reaction buffer (Qiagen Master Mix), 
15 pmol of each primer, 0.5 mM dNTPs and 10 ng of genomic DNA in final volume of 10 
µl. 
 
3.2.3 Generation and genotyping of SftpcCreERT2/+;Rosa26RmiR142/+; Tomatoflox/+ mice 
 
We also generated a knock-in of miR-142 in the Rosa26R locus. The Rosa26-LoxP-STOP-
loxP-miR-142 (aka Rosa26RmiR-142/miR-142) mice were crossed with SftpcCreERT2/+; 
Tomatoflox/flox mice to generate control (Sftpc+/+; Rosa26RmiR-142/+; Tomatoflox/+ ) and 
experimental (SftpcCreERT2/+; Rosa26RmiR-142/+; Tomatoflox/+ ) embryos. The Cre-based 
recombination, allows an irreversible activation of miR-142 expression in the epithelium. 
Table 2. summarizes the procedure and protocols for the detection of   experimental 
SftpcCreERT2/+; Rosa26RmiR-142/+; Tomatoflox/+ and control Sftpc+/+; Rosa26RmiR-142/+; 
Tomatoflox/+mice. 
 
Table 2. Primer sequences and genotyping protocol for mice. 
 
Mouse line Primer Sequence PCR protocol 
  Step Temp°C Time 
SftpcCreERT2/+  
(P1) Fwd- CCC AGT CCC  
TCT CTG AAT TTG  
 
(P2) Rev - GTT TCT ACC 
 GAC CCT GTG AAG  
 
(P3) WT - CAT CGC TCG 
 ACC AGT TTA GTT A 
1 95 3min 
2 95 30min 
3 50 30min 
4 (repeat 
step 2-4, 34 
times) 
72 1 min 
5 72 5 min 
6 4 Hold 
Tomatoflox/+ 1 94 3 min 
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Mouse line Primer Sequence PCR protocol 
  Step Temp°C Time 
(Tom) Fwd - CTG TTC 
CTG TAC GGC ATG G  
 
(Tom) Rev - GGC ATT AAA 
GCA GCG TAT CC  
 
(Wt) Fwd - CCG AAA ATC 
TGT GGG AAG TC  
 
(Wt) Rev - AAG GGA GCT 
GCA GTG GAG TA 
2 94 20 secs 
3 61 30 secs 
4 (repeat 
step 2-4, 34 
times) 
72 30 secs 
5 72 2min 




(Mut) Fwd - AAG CAC TAC 
TAA CAG CAC TGG AGG 
GTG  
 
(Mut) Rev - CAC ACA CCA 
GGT TAG CCT TTA AGC 
CT  
 
(Wt) Fwd - AGC ACG TTT 
CCG ACT TGA GTT GCC  
 
(Wt) Rev - CAC ACA CCA 
GGT TAG CCT TTA AGC 
CT 
1 95 4 min 
2 94 30secs 
3 70 30secs 
4 (repeat 
step 2-4, 34 
times) 
72 1min  
5 72 7min 
6 20 5min 
7 4 hold 
 
3.2.4 Gel electrophoresis 
 
PCR products were analyzed using 1.5% agarose gel containing TAE buffer with Sybrsafe 
(50 µl Sybrsafe + 500ml 1x TAE buffer). 10 µl of PCR products were loaded with 2 µl 
loading dye (BioRad Nucleic Acid Sample loading dye, 5X). The gel was run with 120 V 
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for 60 min. A molecular ladder (QX Size Marker, 100bp-2,5kb Qiagen, Germany) was 
used to detect the expected band sizes. 
 
Table 3. Expected molecular size of genotyping products 
 
Mouse line Expected band size for 
Mutant 
Expected band size for WT 
miR-142 KO 294 174 
Rosa26RmiR-142/+ 411bp 386bp 
SftpcCreERT2/+ 1000 bp 500 bp 
Tomatoflox/+ 196 bp 297 bp 
 
3.2.5 Administration of Tamoxifen (I.P)  
 
Tamoxifen stock solution was prepared by dissolving tamoxifen powder (T5648, Sigma, 
Schnelldorf, Germany) in corn oil at a concentration of 20 mg/mL at room temperature 
(RT).  
 
Pregnant females received a double dose of intraperitoneal (IP) injection of 0.1 mg of 
tamoxifen per gram of body weight at E14.5 and E15.5 respectively. The embryos were 
collected and analyzed at E18.5. Dissected embryos and lungs were examined using 
Leica M205 FA fluorescence stereoscope (Leica, Wetzlar, Germany) and images were 
acquired using Leica DFC360 FX camera.  
 
3.3 RNA extraction, Reverse Transcription-PCR, and Quantitative Real-time PCR 
Analysis 
 
Freshly isolated embryonic lungs were placed in Qiazol lysis reagent, homogenized and 
lysed in GentleMACs (MACS) or Bullet blender (Next Advance). Total RNA was extracted 
using miRNeasy Mini or Micro kit (Qiagen, Hilden Germany) according to manufacturer’s 
protocol. 200ng to 1 µg of RNA was used for cDNA synthesis. RT-PCR for mRNA was 
carried out using Quantitative Reverse Transcription kit (Qiagen).On the other 
hand,TaqMan MicroRNA Reverse Transcription kit (Applied Biosystem) was used to 
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synthesize cDNA for miRNA and 10 ng of total RNA was used. In both cases, reactions 
were assembled following the manufacturer’s recommendations. qPCR was performed 
on a Light Cycler 480 system (Roche Applied Science). The TaqMan microRNA assay 
(Applied Biosystem) was used for screening the differential expression of miRNAs 
whereas SYBR Green (Platinum SYBR Green qPCR SuperMix-UDG Invitrogen) was 
used for the analysis of mRNA expression. U6 and Hprt (Hypoxanthine phosphoribosyl 
transferase 1) were used as a reference for normalization of miRNA and mRNA 
respectively. Results were collected from at least three lung samples and each reaction 
was run in triplicate. Primers for miR142-3p, miR142-5p and U6 were obtained from 
Applied Biosystems whereas primers (Table 4.) for regular genes were designed using 
Roche Applied Science Online Assay Design Tool. All primers were designed to span 
introns and blasted using NCBI software for specificity. 
 
Table 4. Primers used for Real Time-qPCR (Mouse Primers Forward/Reverse)  
 
Gene Forward sequence (5'-3') Reverse sequence (5'-3') 
Hprt cctaagatgagcgcaagttgaa ccacaggactagaacacctgctaa 
Fgf10 atgactgttgacatcagactcctt cactgttcagccttttgagga 
Fgfr2b cctacctcaaggtcctgaagc catccatctccgtcacattg 
Fgfr2c tgcatggttgacagttctgc tgcaggcgattaagaagacc 
Fgfr1b tgggtcggtgcggagatcgt acggacaacaacaaaccaaaccct 
b-catenin gcagcagcagtttgtgga tgtggagagctccagtacacc 
Lef1 tcctgaaatccccaccttct tgggataaacaggctgacct 
Etv5 Gtggccgctcaggagta gtgcttccaaagtctccgct 
Spry2 gagaggggttggtgcaaag ctccatcaggtcttggcagt 
Ep300 acatgatgcctcggatgact tagggggctgtggcatatt 
Apc catggaccaggacaaaaacc gaacacacacagcaggacaga 
gp130 aggaccaaagatgcctcaac tgaaggaagttcgaggagaca 
Kras tggatgagtacgaccctacga tccctcattgcactgtactcc 
Pdpn ggatgaaacgcagacaacag agctctttagggcgagaacc 
Sftpc ggtcctgatggagagtccac gatgagaaggcgtttgaggt 
Scgb1a1 gatcgccatcacaatcactg cagatgtccgaagaagctga 
Epcam tgtcatttgctccaaactgg gttctggatcgccccttc 
Aqp5 taacctggccgtcaatgc gccagctggaaagtcaagat 
Ecad gttgcagaaggcgctgtt gtgttgacgtcatcgtctgc 
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Gene Forward sequence (5'-3') Reverse sequence (5'-3') 
P63 agacctcagtgaccccatgt ctgctggtccatgctgttc 
Bzrap1 agagagccctgggtacagc cccgaagcctatgttgaact 
LincRNA 
(A430104N18Rik) cttcctgacccctgatacttg cccatatcctcacggacg 
 
3.4 In-situ hybridization and immunofluorescence staining 
 
Freshly isolated lungs were washed in PBS, then fixed in 4% PFA, gradually dehydrated 
in ethanol, impregnated with xylene, embedded in paraffin and sectioned into 5 µm slices 
on poly-L-Lysine-coated slides. Antigen retrieval was performed by treating the sample 
with Proteinase K for 30 secs at 37°C. The slides were blocked 2 times 5 min with Dako 
(DAB Emission +Dual Linksystem HRP, Life Technologies) and then incubated with 
digoxygenin labeled LNA probes (Exiqon, miRCURY LNA Detection probe, Vedback, 
Denmark) specific for miR142-3p and miR142-5p. For immunofluorescence staining the 
slides were de-paraffinized blocked with 3% bovine serum albumin (BSA) and 0.4% Triton 
X-100 (in Tris-buffered saline (TBS) at room temperature (RT) for 1 hour and then 
incubated with primary antibodies against Apc (ab15270, Abcam; 1:200), phospho-S552-
b-catenin (9566,Cell Signaling; 1:200) Ep300 (sc-585,Santa Cruz; 1:200) ,Pro-Surfactant 
Protein C (AB3786, Millipore; 1:500), T1 alpha /Podoplanin (8.1.1,DSHB - Univ of 
Iowa;1:250),Cdh1/E-Cadherin (610181, BD Lab; 1:250), pErk (4376, Cell 
Signaling;1:250),Ki67 (NB600-1252, Novus Biologicals; 1;250) and Fgfr2-BEK (C-17) (sc-
122, SantaCruz;1:250) at 4°C overnight. After incubation with primary antibodies, slides 
were washed three times in TBST (Tris buffer saline + 0.1% Tween 20) for 5 minutes, 
incubated with secondary antibodies at RT and washed three times with TBST before 
being mounted with Prolong Diamond Anti-fade Mountant with DAPI (4’,6-diamidino2-
phenylindole; Invitrogen). Photomicrographs of immunofluorescence staining were taken 
using a Leica DMRA fluorescence microscope with a Leica DFC360 FX camera (Leica, 
Wetzlar, Germany). Figures were assembled using Adobe Illustrator. The data are 
representative of at least three lungs from independent experiments. Antigen retrieval for 
some of the immuno-fluorescence staining was performed using citrate buffer for 10min 
at 100°C followed by cooling on ice for 15 min. 
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Table 5. Probes and fluorescent antibodies/dyes used for fluorescence  
in-situ hybridization 
 
Probes Company (Catalog number) Dilution 
hsa-miR-142-3p EXIQON mercury LNA™ microRNA 





EXIQON mercury LNA™ microRNA 





Company (Catalog number)  
Anti-Dioxigenin-POD, Fab 
fragments 
Roche Diagnostics (11207733910) 1:400 
Dako EnVision® + Dual Link 
System-HRP (DAB+) 
Dako Agilient Technologies 
K406511-2 
 
Prolong Diamond Anti-fade 
Mountant with DAPI 
Invitrogen (P369362)  
 
 
Table 6. Antibodies used for immunofluorescence. 
 
Antibody Company (Catalog number) Dilution 
Ki67 Novus Biologicals (NB600-1252) 1:250 
Cdh1/Ecad BD Transduction Laboratories  (610181) 1:250 
Pro-Sftpc Millipore (AB3786) 1:500 
Podoplanin Develpomental Studies Hybridoma Bank 
University of Iowa (8.1.1) 
1:250 
Apc Abcam (ab15270) 1:250 
Ep300 (c-20) SantaCruz (sc-585) 1:250 
b-catein pS-552 Cell Signaling (9566s) 1:250 
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Antibody Company (Catalog number) Dilution 
pErk Cell Signaling (4376) 1:250 
Fgfr2-BEK(C-17) SantaCruz  (sc-122) 1:250 
 
3.5 Murine peripheral blood counts 
In the Mfd diagnostics facility, about 250 µl of whole blood was retro-orbitally drawn from 
8 weeks-old sex-matched miR-142 KO and wild type littermates into glass capillary tubes 
containing 5 µl of 0.5 M EDTA, to prevent coagulation. ADVIVA2120 Hematology System 
(Siemens Healthcare, Germany) was used to perform complete blood count 
measurements. Blood count measurement was performed at Justus-Liebig Universität 
Klinik fur Kleintiere (Central laboratory for small animals), Giessen Germany. 
 
3.6 Hematoxylin and Eosin stain 
 
3 – 5 um sections of the left lobe were deparaffinized, dipped in water and stained for 
Mayer’s Hematoxylin solution for 1–3 min and washed under running tap water for up to 
10min. Slides were monitored under the microscope for over and under staining. Slides 
were then incubated for 2 min in Eosin dye and brought back through increasing gradients 
of EtOH, xylene and cover slipped with pertex mounting media.  
 
3.7 Flow cytometry analysis and fluorescence activated cell sorting 
 
Lungs were dissected, washed with HBSS and kept on ice. Then, they were cut into fine 
pieces using a sharp blade before being digested with 0.5% Collagenase Type IV/HBSS 
(Life Technologies, Invitrogen) at 37°C for 45 min. Once homogenate was dissociated, the 
cell suspension was successively passed through 18, 21 and 24G syringes before being 
passed through 70 and 40 μm cell strainers (BD Biosciences, Heidelberg, Germany).One 
volume of  HBSS buffer was added to the sample to dilute the collagenase and then 
centrifuged at 1200rpm for 10 minutes to remove the enzyme solution. Cells were then 
resuspended in cold FACS buffer (1xPBS;2%FBS;1mM EDTA;0.1% sodium azide: for 
FACS measurement), and or MACS buffer (1xPBS;2%FBS;1mM EDTA : for cell sorting). 
Cells were incubated with fluorochrome labeled antibodies (Table 6) for at least 15 min on 
ice in the dark and then centrifuged at 2000 rpm for 5 min and resuspended in FACS buffer 
or MACS buffer. FACS measurements were carried out using LSRFortessa equipped with 
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FACS DIVATM software for analysis and FACSAria III cell sorter for isolation of epithelium 
and mesenchyme and isolation of AT2 cells (BD Biosciences).  
 
3.7.1 Measurement of AT1 and AT2 cell number  
 
Following antibodies were used for analysis of AT1 and AT2 cell number [488-CD31 (1:50), 
Biolegend, Cat-102513; FITC-CD45 (1:50), Biolegend, Cat-103108; Apc Cy7 EpCam 
(1:50), Biolegend, Cat-118217 or Apc–eFluor-780-EpCam (1:50), eBioscience, Cat-47-
5791-80; proSPC (1:500), Millipore, Cat-AB3786; Apc-Podoplanin (1:20), Biolegend, Cat-
127409; Apc Isotype Ctrl (1:20), Biolegend, Cat-402012] and samples were analysed 
using LSRFortessa equipped with FACS DIVATM software. 
 
3.7.2 Isolation of epithelium and mesenchymal cells as well as isolation of AT1 and 
AT2 cells from embryonic lungs 
 
For the isolation of epithelium and mesenchyme we used following antibodies [488-CD31 
(1:50); FITC-CD45 (1:50); Apc Cy7 EpCam (1:50)] whereas [488-CD31 (1:50); FITC-CD45 
(1:50); Apc Cy7 EpCam(1:50), Apc-Podoplanin (1:20); Apc Isotype Ctrl(1:20)] antibodies 
were used for isolation of AT1 and AT2 cells.The samples were then passed through 
FACSAria III cell sorter. 
 
Table 7. Antibodies used for FACS. 
 
Antibody Company (Catalog 
number) 
Dilution 
Pro Surfactant Protein C (pro-Sftpc)  
Antibody 
Millipore (AB3786) 1:500 
T1alpha (Podoplanin) APC anti-mouse Biolegend (127409) 1:20 
Epcam (CD326) APC/Cy7 Biolegend (118217) 1:50 
Epcam (CD326) APC-eFlour780 eBiosciences (553079) 1:50 
Alexa Fluor 488 anti-mouse CD31  Biolegend (102513) 1:50 
BD Pharmingen FITC Rat Anti-Mouse CD45 
(clone 30-F11) 
Biolegend (103108) 1:50 
PE anti-human/mouse CD49f Antibody Biolegend (313611) 1:50 
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Antibody Company (Catalog 
number) 
Dilution 
Rabbit serum Sigma-Aldrich (R9133) 1:500 
F(ab´)2-Goat anti-Rabbit IgG (H+L) 





Neg. control for T1alpha: APC Syrian Hamster 
IgG Isotype control 
Biolegend (402012) 1:20 
Fc Block Gamunex10% Bayer (TAL-05-0002) 1:10 
Saponin Cabiochem (558255) 0.02% 
 
3.8 Microarray experiments 
 
RNA was isolated using the RNeasy Mini Kit (217004; Qiagen). Purified total RNA was 
amplified using the Ovation PicoSL WTA System V2 kit (NuGEN). Per sample, 2 µg 
amplified cDNA was Cy5-labeled using the SureTag DNA labeling kit (Agilent). 2 µg of the 
labeled cDNA were hybridized on Agilent-074809 SurePrint G3 Mouse GE v2 8x60K 
Microarrays for 22h at 65°C in Agilent hybridization chambers. The cDNA was not 
fragmented before hybridization. Dried slides were scanned at 2 µm/pixel resolution using 
the InnoScan IS900 (Innopsys). The analysis was performed with R and the Limma 
package. Gene set analyses were done using the Wilcoxon-tests of the t-statistics. The 
data are deposited in GEO and are available through the accession number GSE106411.  
 
3.9 Embryonic lung explant culture 
 
Timed-pregnant wild-type mice were sacrificed on E14.5, the embryonic lungs were 
harvested and placed on 8 μm Nucleopore Track-Etch membranes (110414; Whatman). 
Vivo-morpholinos specific for miR-142-3p and/or miR-142-5p (Gene Tools LLC) were 
added at 5 μM to E14.5 lung explants. Lungs were grown for 96 hours at 37°C with 5% 
CO2 prior to analysis. In a second set of experiments, 100 μM Dexamethasone (Dex, 
D1756; Sigma Aldrich), 10 μM IQ-1 (Ep300-Ctnnb1 inhibitor, S8248; Selleckchem), 10 μM 
SCH772984 (Erk inhibitor, 19166; CayMan Chemical) either alone or in combination with 
morpholinos were added to the E14.5 lung explants.  
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3.10 Western blotting 
 
Protein samples from either E18.5 embryonic lung samples or cultured lung explants were 
isolated using RIPA buffer (Santa Cruz) containing protease inhibitor cocktails. Equal 
amounts of total protein from each assayed sample were used for chemiluminescent 
Loading buffer (5% SDS in bromophenol blue and b- mercaptoethanol- Biorad) was added 
to protein samples, denatured 5 min at 95°C and cooled on ice. 15 µg of protein sample 
was loaded on a 12% polyacrylamide gel and run at 35mA, 100volt for 1hour. Samples 
were then electrically transferred to a polyvinylidene fluoride (PVDF) membrane (MilliQ)- 
by semi-dry electro blotting (100mA, 24 volts per Gel, Gel size: 7x9 cm) for 90 minutes. 
The membrane was blocked with 5% Bovine Serum Albumin or 5% Milk in TBS-T at room 
temperature on a shaker for 1 hour followed by incubation with primary antibody (Table 8.) 
and overnight at 4°C. After washing the membrane with TBS-T five times for 5 minutes 
each, the membrane was incubated with the respective HRP-labeled secondary antibody 
(1:1000) at room temperature for 1 hour followed by 5 times washing with TBS-T for 5 
minutes each. The protein bands were detected by ECL (Enhanced Chemi-luminescence, 
Amersham, Germany) treatment followed by exposure to the membrane. Immunoblotting 
was performed using antibodies against proSPCP (1:500) 9 (Millipore) and beta-actin 
(1:50000) (Abcam). 
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3.11 Statistical analysis 
 
Data were assembled using Graph Pad Prism Software (Graph Pad software, USA) and 
presented as average values ± S.E.M. Statistical analyses were performed using Student’s 
t-test. Data were considered significant if p < 0.05. Figures were assembled using Adobe 






4.1  Generation of miR-142 KO mice 
 
In mice, the miR-142 gene (ENSMUSG00000065420) is located on chromosome 11 (Fig. 
5). miR-142 is positioned directly adjacent to an exon for a long non-coding RNA 
(A430104N18Rik ENSMUSG00000084796), which function is still unknown so far. 
Benzodiazepine receptor (peripheral) associated protein 1 (Bzrap1, 
ENSMUSG00000034156) is also another gene found downstream of miR-142. The miR-
142 locus also contained many GC rich repeat regions, which render PCR amplification 
and screening difficult. The constitutive and complete deletion of the miR-142 gene was 
therefore carried out and mice heterozygous for the miR-142 KO allele were generated. 
Fig. 6B shows the genotyping results of E18.5 embryos arising from miR-142 
heterozygous crosses. Fig. 6C shows the validation of our primer sets to amplify either the 
wild-type miR-142 allele (P2/P3), the presence of the LoxP site (P1/P4) or the miR-142 






Figure 5. Schematic representation of miR-142 locus on the chromosome 11 of the 
mouse genome. miR-142 is located at proximity of an exon of a long non-coding RNA 
(LncRNA). An exon of LncRNA will be removed while deleting miR-142. Benzodiazepine 
receptor (peripheral) associated protein 1 (Bzrap1) is also another gene found 






Figure 6. Genotyping strategy for miR-142 KO allele. A) Schematic diagram showing 
WT mice miR-142 locus, targeted allele and knock out allele. P1, P2, P3 and P4 represent 
the specific primers used for differentiating wild type and knock out allele. B-C) PCR 
analysis of the genomic DNA obtained from the embryos at E18.5 from miR-142+/- (Hets) 
male and female intercrossing. 254 bp band size for KO allele (Primers used: P1 and P3) 
and 174 bp band size for WT allele (Primers used: P2 and P3) was determined. A 105 bp 
band was observed using LoxP specific primers (P1 and P4). 
 
4.2 miR-142 KO pups are born alive and display no obvious abnormalities 
 
Litters from miR-142 heterozygous crosses were genotyped at E12.5, E18.5 and 
postnatally. Although the expected Mendelian ratio for generating knockout (KO) pups 
from crossing two hemizygous mice is 25%, this ratio appeared higher when embryos 
were harvested at E12.5 (39%) and E18.5 (40%) (Table 9). The likely explanation for this 
observation is the low number of harvested embryos (eighteen and fifteen respectively). 
Another important conclusion from these data is that miR-142-KO embryos are not dying 
in utero. In addition, individual monitoring and genotyping of all the neonates born from 
different litters up to 4 months of age indicate a normal representation of miR-142-KO 
mice (20% of the overall postnatal mice (n=79)). In the miR-142-KO group, only one 4-




between the ages of 3 and 4 months. None of the mice died in the control wild-type group. 
Overall, our data indicate very low death rate in the miR-142-KO group postnatally. 
 
Table 9. Numbers of embryos obtained at different stages of embryonic 
development 
 
  (# 3 animals died at the age of 2-3 months, * 1 animal died at the age of 4 month) 
 
4.3 miR-142 deletion abolishes the expression of miR-142-3p and miR-142-5p 
 
Our experimental approach was designed to carry out the complete deletion of miR-142. 
In the process of deleting miR-142, one exon for the LncRNA, close to miR-142, had also 
to be deleted. In addition, the expression of the Benzodiazepine receptor (peripheral) 
associated protein 1 (Bzrap1), a gene encoding a regulator of synaptic transmission, might 
also be disturbed as the proposed deletion encompasses also part of the 5’ region of this 
gene. To confirm the successful deletion of miR-142, RNA from E18.5 lungs from miR-
142+/+, miR-142+/- and miR-142-/- littermate embryos (n= 3 for each genotype) were 
isolated. qPCR analysis showed that the expression of miR-142-3p and miR-142-5p were 
reduced in miR-142 heterozygous lungs compared to wild-type lungs. In addition, the 
expressions of these 2 isoforms were completely abolished in miR-142 KO lungs (Fig. 7A-
B). We also tested the expression of the Bzrap1, a gene, positioned 3.5kb downstream of 
miR142. Bzrap1 expression level was unchanged in miR-142 heterozygous or KO lungs 
compared to that of wild-type littermates, (Fig. 7C) confirming that the promoter region of 
Bzrap1 gene was not impaired. As expected, the expression of the LncRNA was 
abrogated in both miR-142 heterozygous and KO embryos (Fig. 7D). 
 
In-situ hybridization experiments, using specific digoxygenin labeled probes for these two 
microRNAs showed that the miR-142-3p and miR-142-5p are expressed in both the 
mesenchyme as well as in the epithelium of the E18.5 lung (Fig. 8 A, B, E, F). The levels 
of expression of both microRNAs were significantly decreased in miR-142 KO samples 







E12.5 3 (17%) 8 (44%) 7 (39%) 18 
E18.5 3 (20%) 6 (40%) 6 (40%) 15  




compared to that of the WT samples (Fig. 8 C, D, G, H vs. A, B, E, F). The unbiased 
quantification of the expression of the respective isoforms of miR-142 confirms the very 




Figure 7. Deletion of miR-142 successfully abrogates miR-142-3p and miR-142-5p 
expression. A-B) qPCR analysis on cDNA obtained from E18.5 embryonic lung sample 
showed that both miR-142-3p and miR-142-5p were down regulated in miR-142+/-(Hets) 
lungs and completely absent in miR-142-/-(KO) lungs as compared to miR-142+/+(WT) 
samples. C) The levels of Bzrap1 gene, positioned 3.5kb downstream of the miR-142 
gene, remain unchanged as compared to that of wild type littermates shown. D) 







Figure 8. In-situ hybridization on E18.5 miR-142-/- (KO) embryonic lung sections.  
 In-situ hybridization for miR-142-3p (A-D) and miR-142-5p (E-H) showing significant 
reduction of the corresponding expression levels in miR-142-/- compared to WT 18.5 
embryonic lung sections. (I-J). Quantification of the in-situ hybridization signals indicating 
a strong reduction of both isoforms. Scale bar represents 10µm. 
 
4.4 miR-142-KO mice display a wide range of hematological disorder 
 
miR-142 is highly expressed in hematopoietic cells belonging to both the myeloid and 
lymphoid lineages. Using an exogenous gene trap technology, Chapnik and colleagues 
recently reported the phenotypic analysis of miR-142 knockdown mice. Their mutant mice 
displayed an array of hematological defects (Chapnik et al., 2014). In order to validate our 
mouse model, we performed total blood count on 8-week-old miR-142+/+(WT) and miR-
142-/- (KO) mice (n=3 for each genotype). Our results also indicated a significant decrease 




miR-142 KO vs. wild-type animals (Fig. 9 B-E, G). A significant increase in mean platelet 
volume was also observed (Fig.9 D, F). 
		
Figure 9. miR-142 KO mice display hematological abnormalities.  
(A) Schematic representation of hematopoietic stem cells differentiated into different 
blood cell types. Peripheral blood cell count in 8-week-old miR-142-/- mice (n=3) showing 
a significant decrease in circulating white blood cells (B), lymphocytes (C), platelets (D), 
eosinophils (E) and monocytes (G) in addition to an increase in mean platelet volume (F) 
 
4.5 Enhancement of alveolar epithelial lineage formation via the activation of the 
glucocorticoid pathway leads to decreased miR-142 expression 
 
Our in-situ hybridization data indicated miR-142-3p and -5p are expressed in both the 
epithelium and the mesenchyme at E18.5 (Shrestha et al., 2015).This  suggests, in 
addition to its reported role in the mesenchyme (Carraro et al., 2014), miR-142 could also 




alveolar epithelial lineage formation during lung development. First, we took advantage of 
an in vitro model previously reported where activation of the glucocorticoid receptor 
pathway with dexamethasone increases alveolar epithelial lineage formation (Laresgoiti et 
al., 2016). Treatment of E14.5 embryonic lungs grown in vitro for 4 days with 
dexamethasone (Dex) (Fig. 10A) led to increase in the expression of both AT1 (Aqp5, 
Pdpn) and AT2 markers (Sftpc) (Fig. 10C). The impact of Dex treatment on Sftpc at the 
protein level was confirmed by immunofluorescence staining (IF) (Fig. 10E).  Next, we 
investigated the impact of dexamethasone treatment on the expression of the specific miR-
142 isoforms. We observed a strong decrease in miR-142-3p and -5p expression upon 
Dex treatment (Fig. 10B) associated with a significant increase in miR-142 targets Apc, 
Ep300, gp130 but not Kras (Fig. 10D). These results suggested that some of the effects 
of dexamethasone on alveolar epithelial lineage formation could be due to decrease in 








Figure 10. Effect of dexamethasone (Dex) on E14.5 embryonic lung cultured in vitro 
for 4 days. (A) Experimental design. (B) qPCR analysis showing the expression level of 
miR-142-3p and miR-142-5p as well as the expression of (C) Sftpc, Aqp5, Pdpn and 
Fgfr2b. (D) Apc, Ep300, gp130 and Kras (E) IF staining for Sftpc on E14.5 lung explants 




4.6 miR-142-3p and miR-142-5p are expressed in both the AT1 and AT2 lineages 
during lung development 
 
In order to investigate whether both miR-142-3p and miR-142-5p are expressed 
specifically in the AT1 and AT2 cells, we performed fluorescence in-situ hybridization 
specific to the  miR-142-3p and -5p, co-stained together with either Sftpc (AT2 marker) or 
Pdpn (AT1 marker) at three different time points (E16.5, E17.5, and E18.5) during alveolar 
lineage formation (Fig. 11A). We observed the expression of the miR-142-3p and -5p in 
the AT1 and AT2 cells as detected by the co-expression of miR-142-3p and miR-142-5p 
either wtih Sftpc or Pdpn.Co-expression of miR-142-3p or miR142-5p with Sftpc was 
observed in all the stages considered but on the other hand, the co- expression of these 
miRs with Pdpn at E16.5 was not visible. However, at E17.5 and E18.5, we clearly 
observed cells co-expressing miR-142-3p or 5p with Pdpn. These results indicate that 
both the microRNAs are expressed in the alveolar epithelium during development. Using 
FACS based approach, with a combination of antibodies like CD45 and CD31 to exclude 
the hematopoietic and endothelial cells as well as Epcam for capturing epithelial 
(Epcam+ve) or mesenchymal (Epcam-ve) cells, we isolated resident epithelial and 
mesenchymal lung cells at E14.5, E16.5 and E18.5 and examined miR expression by 
qPCR (Fig. 11B). The validation of this approach was carried out for known epithelial 
(Cdh1, Epcam, Fgfr2b) or mesenchymal (Fgf10, Acta2, Vimentin) markers (Fig. S1A-B). 
The expression of miR-142-3p is higher in the mesenchyme than in the epithelium at 
E16.5 and E18.5 but not at E14.5. Interestingly, between E14.5 and E18.5, miR-142-3p 
expression in the epithelium progressively decreases while the expression of its bona fide 
targets Apc, Ep300, gp130, and Kras were increased (Fig, S1C). Consistent with our 
previous observations, miR-142-5p was expressed at a much lower level than miR-142-
3p (Carraro et al., 2014).  
 
We also investigated the expression of these two microRNAs in E16.5, E17.5 and E18.5 
FACS-isolated AT1 and AT2 cells (Fig. 11C). At E16.5, the captured cells for both lineages 
are likely to be the common bipotent progenitors(Desai et al., 2014; Treutlein et al., 2014). 
For the AT1 lineage, miR-142-3p was expressed at a similar level between E16.5 and 
E18.5. On the contrary, the expression of miR-142-5p increased as the formation of the 
AT1 lineage progressed. Similar expression patterns for miR-142-3p and 5p were 
observed in the formation of the AT2 lineage. Interestingly, we noted the higher 
enrichment of miR-142-5p in AT1 compared to AT2 cells at E18.5. Furthermore, data 




transcriptomic data at E18.5 previously published and generated by Treutlein et al., 2014 
was carried out (Fig. 11D). No differences in the expression level of miR-142 targets were 
observed in AT1 vs. AT2 cells. However, we noticed a higher number of cells in the AT2 
pool expressed Apc and Ep300 (7/12 and 5/12, for Apc and Ep300 respectively) compared 
to AT1 (12/41 and 10/41, for Apc and Ep300 respectively) (Fig. 11D). This supports our 
previous result that miR-142 expression is low in AT2 compared to AT1 cells. Interestingly, 
a higher number of cells in the AT1 compared to AT2 pools expressed Kras (19/41 and 
2/12, for AT1 and AT2 respectively) suggesting that Kras expression level is not regulated 
by miR-142 in AT1 cells. gp130 was expressed by a low number of cells in the AT1 and 
AT2 pools (3/41 and 1/12, for AT1 and AT2, respectively).  Altogether, the increase in 
these miR-142 targets appears to occur more in AT2 than AT1, confirming the observed 




Figure 11. Gene expression analysis during lung development of miR-142-3p and 
miR-142-5p. (A) In-situ hybridization of miR-142-3p or 5p and co-immunofluorescence 
staining for either Sftpc (AT2 marker) or Pdpn (AT1 marker). (B) qPCR on FACS-isolated 
lung epithelium and mesenchyme at E14.5, E16.5 and E18.5. (C) qPCR on FACS-isolated 
AT1 and AT2 cells at E16.5 (Bipotent cells), E17.5 and E18.5. (D) Mining of single cell 
transcriptomic data (derived from Treutlein et al., 2014) for AT1 and AT2 cells at E18.5. 




4.7 miR-142 KO lungs display alteration of epithelial integrity starting at the 
pseudoglandular stage  
 
In order to explore further, the function of miR-142 during lung development, we analysed  
the impact of loss of miR-142 in our newly generated miR-142 KO mice (Shrestha et al., 
2015). Phenotypic analysis of the E12.5 embryonic lungs of Control and KO littermate 
indicated no obvious macroscopic abnormalities in terms of branching (Fig. 12A). This 
result was quite surprising as we reported previously that the knock down of miR-142-3p 
using morpholino specific to miR-142-3p in lungs grown at E11.5 in vitro led to impaired 
branching and decreased Ctnnb1 signaling in association with increased Adenomatous 
polyposis coli (Apc) expression and arrested proliferation in the lung mesenchyme,  
(Carraro et al., 2014). The lack of obvious branching phenotype in E12.5  miR-142 KO 
lungs suggested that miR-142-5p could also play a functional role. An upregulation of Apc 
and Ep300, known targets for miR142-3p and miR-142-5p respectively appeared to be 
upregulated in KO lungs (Fig. 12B, C). Further, in vitro knock down experiment using 
morpholinos against miR-142-3p (mo-3p), -5p (mo-5p) or (3p+5p) (mo-(3p+5p)) indicated 
that the simultaneous inactivation of both isoforms leads to the rescue of the branching 
defects reported upon miR-142-3p knockdown alone (Fig. 12D). Interestingly, the 
expression level of Apc, Ep300, and Kras were not significantly altered at the RNA level 
from E12.5 mir-142 KO lung samples, indicating complex gene regulation/compensation 
(Fig. S2A). However, an increase in Wnt signaling pathway targets like Lef1 and Ctnnb1 
suggested increased Wnt signaling.  
 
Careful examination of E12.5 miR-142 KO lung epithelium, by immunofluorescence for 
Cdh1, suggested a disruption in the epithelial cuboidal cell morphology, and acquisition of 
round shape with the overall disorganization of the epithelial layer (Fig. 12B). Global 
transcriptomic analysis using gene arrays with RNA originating from the whole Control 
and KO E12.5 lungs was also carried out. The heat map (Fig. S2C) shows sets of up- or 
down-regulated genes selected based on their p-value in Control and KO lungs (n=3). 
KEGG analysis indicated perturbations in pathways involved in regulation of actin 
cytoskeleton, focal adhesion, and endocytosis as well as ECM receptor interaction. All 
these pathways, which have been shown to modulate epithelial integrity and maturation, 
may be involved in the observed phenotype. Interestingly, PI3K-Akt, Mapk, Ras, Hippo, 







Figure 12. Analysis of the miR-142 KO at E12.5. (A) Bright field picture and Cdh1 
staining of Control (WT) littermate and miR-142 KO lungs at E12.5. Immunofluorescence 
for (B) Apc, (C) Ep300 and (D) In vitro culture of E11.5 embryonic lung explants, treated 
with scramble, mo142-3p, mo142-5p and mo142-3p+5p. Scale bar represents 10µm. 
 
4.8 The alveolar epithelial lineage is perturbed in E18.5 miR-142 KO lungs 
 
Macroscopic analysis of the E18.5 KO lungs indicated no obvious changes in terms of size 
or shape when compared to wild-type littermates. Analysis of the microscopic phenotype 
by H&E staining (n=3) also revealed no major structural abnormalities (Fig. 13A). Gene 
expression analysis by qPCR on the whole lung indicated that the AT2 marker, Surfactant 
protein C (Sftpc) was upregulated in KO vs. Control lungs (p=0.0074, n=3) (Fig. S3C).	Both 
immunofluorescence and western blot analysis confirmed an increase in the number of 




Podoplanin (Pdpn) (p=0.06, n=3) and Club cell marker Scgb1a1 showed a trend towards 
increase, however, the expression of basal cell marker p63 was unchanged (Fig S3C).  
Flow cytometry analysis using Epcam, CD49f, Pdpn antibodies showed an increase in the 
percentage of AT2 cells (84.9% ± 0.2% vs. 79.8% ± 1.04% in KO vs. Control, respectively, 
p=0.002, n=3), and a decrease in the percentage of AT1 cells (9.05% ± 0.68% vs. 12.3% 
± 0.66% in KO vs. Control, respectively, p=0.004, n=3) (Fig. 13C). Similar results were 
obtained using Epcam, Epcam, Sftpc and Pdpn antibodies (Fig. S3A,B). Analysis of  Ki67 
immunoreactivity, in the alveolar epithelial layer of Control and KO lungs at E18.5, 
indicated no changes in epithelial proliferation (Fig. S3D). Furthermore, no changes in the 
percentage of Epcam-positive cells (Epcam+ve) (over total cell population) were observed 
(Fig. 13C), suggesting that loss of miR-142 is not affecting overall, epithelial proliferation. 
Co-immunofluorescence staining for Sftpc and Pdpn further demonstrated an increased 
AT2 and decreased AT1 cell number in E18.5 miR-142 KO embryos (Fig. 13D). 
 
We also explored the status of Fibroblast growth factor 10 (Fgf10) signaling, a key pathway 
reported influencing alveolar epithelial lineage formation (Chao et al., 2017; Ramasamy et 
al., 2007).  We found that the expression of Fgf10 was not changed but a very significant 
increase in the expression of its receptor, Fgfr2b, in KO vs. Control lungs (p= 0.0018) was 
observed (Fig. S4A). The level of expression was also validated at the protein level by 
immunofluorescence staining (Fig. S4B). Analysis of Sprouty2 and Etv5, two previously 
reported Fgf10 downstream targets (Herriges et al., 2015; Mailleux et al., 2001), showed 
no significant difference between Control and KO lungs, suggesting that Fgf10 signaling 
per se was not affected.  
 
Next, we carried out gene arrays from Control and KO FACS-isolated AT2 cells and 
examined their differentiation state using the previously reported comprehensive AT1 and 
AT2 gene signatures (Treutlein et al., 2014). We observed a sharp difference in gene 
expression among the four KO samples (Fig 13E, KO vs. Control, n=4; Fig. S5A). In 
particular, two KO samples showed a strong upregulation of the AT1 signature and 
decreased AT2 signature. The other two KO samples behaved more like Control samples. 
Interestingly, FACS analyses of these samples were consistent with the KO phenotype 
(increased AT2 and decreased AT1 cell number). In addition, the heat maps (top 100 
genes according to p values, Fig. S5B) shows that these samples are clustering with KO 
samples and not Control samples. The reason for the observed heterogeneity in the AT1 
and AT2 signature between the different KO samples is not clear and could reflect 




reflect an attempt by the mutant lung to compensate for the loss of the AT1 cells. As the 
AT2 cells have been shown to serve as progenitors which self-renew and give rise to the 
AT1, an increase in the AT1 signature in the mutant AT2 cells could reflect compensatory 
mechanisms and would not directly be linked to an additional function of miR-142 in AT2 
alveolar differentiation.  In spite of this overall variability between mutant samples, gene 
set analysis, which takes into consideration the four samples from each group, indicated 
a significant increase in the AT1 signature (p≤0.01) and a decrease in the AT2 signature 
(p≤0.01).  In conclusion, we demonstrate increased AT2/AT1 ratio in KO vs. Control lung, 
as well as decreased AT2 gene signature in KO vs. Control AT2 cells.  
 
We also examined miR-142 targets on E18.5 miR-142 KO lungs by qPCR. Significant 
changes were observed in Apc, Ep300, gp130 and Kras expression. The expression of 
Wnt components Lef1 and Ctnnb1, which are not miR-142 targets, was not significantly 
affected (Fig. S2B). We further validated these observations at the protein level by 
immunofluorescence. Apc (Fig. 13F) and Ep300 (Fig. 13G) appeared to be up-regulated 
in KO lungs. The level of activated beta-catenin (pS552Ctnnb1) was increased in KO lungs 
compared to Control lungs suggesting increased Wnt signaling (Fig. 13H).  Finally, we 









Figure 13. Analysis of the alveolar epithelial lineage phenotype of the miR-142 
Control and KO lungs at E18.5. (A) Bright field pictures, H & E staining of Control and 
miR-142 KO lungs at E18.5. (B) IF and WB analysis for Sftpc expression and 
corresponding quantification of the number of Sftpc-positive cells. (C) Flow cytometry of 
Control and miR-142 KO lungs for AT1 and AT2 cells. (D) Pdpn/Sftpc/DAPI IF staining in 
Control and KO E18.5 lungs. (E) AT1 and AT2 gene signature analysis in FACS-isolated 
AT2 cells from E18.5 miR-142 KO lungs. Immunofluorescence for (F) Apc (G) Ep300 (H) 




4.9 Impact of cell autonomous over-expression of miR-142 in alveolar 
progenitors  
 
The expression of miR-142 in the epithelium, as well as the epithelial alveolar lineage 
phenotype upon global loss of function of miR-142, suggested that miR-142 could play a 
cell-autonomous role in the epithelium. To test this possibility, we generated a knock-in of 
the LoxP-Stop-LoxP-miR142 cassette in the Rosa26 locus (Rosa26RmiR-142/miR-142). We 
crossed the Rosa26RmiR-142/miR-142 mice with SftpcCreERT2/+; Tomatoflox/flox mice, to generate 
Control Sftpc+/+; Rosa26RmiR-142/+; Tomatoflox/+ and gain of function (GOF) SftpcCreERT2/+; 
Rosa26RmiR-142/+; Tomatoflox/+ embryos. This Cre-based recombination allows an 
irreversible activation of miR-142 expression in the epithelium. The expression of miR-
142 was induced with tamoxifen IP injection at E14.5 and E15.5. The resulting lung 
phenotype was analyzed at E18.5 (Fig. 14A). Experimental lungs were detected via the 
expression of the red fluorescent protein (RFP) in the epithelium and confirmed by 
genotyping. Validating our approach, we found increased miR-142-3p (p=0.0024) and -5p 
(p=0.0004) expression in GOF vs. Control lungs (Fig. 14B). FACS analysis of 
CD49flow/Epcamint alveolar epithelial cells as well as AT1 (Pdpn+ve) and AT2 (Pdpn-ve) cells 
indicated no change in the percentage of AEC cells (over total cell population). However, 
a significant decrease in the percentage of AT2 cells (82.4% ± 1.24% vs. 86.6% ± 0.99% 
in GOF vs. Control, p=0.004, n=4) and an increase in the percentage of AT1 cells (10.6 ± 
0.88% vs. 8.7 ± 0.38 in GOF vs. Control, p=0.001, n=4) was observed. Co-
immunofluorescence staining for Sftpc and Pdpn also indicated a decrease in AT2 and an 
increase in AT1 cell number in E18.5 GOF embryos compared to Control (Fig. 14D). 
 
Next, we carried out gene arrays from E18.5 Control and GOF FACS-isolated AT2 cells 
and examined the state of differentiation of these cells using the AT1 and the AT2 gene 
set signature. Fig. 14E displays the heat maps comparing the expression of the AT1 
signature and the AT2 signature in Control and KO (n=4) AT2 (refer to Fig. S5D for higher 
magnification). Our results indicated a decrease in the AT1 signature associated with an 
increase in the AT2 signature in the AT2 cells. Gene set analysis indicated a small but 
significant decrease in the AT1 signature (p≤0.001) and an increase in the AT2 signature 
(p≤0.001). 
 
In conclusion, a gain of miR-142 expression in alveolar epithelial cells indicated a 
decreased AT2/AT1 cell ratio with the increased AT2 gene signature in AT2 cells, which 






Figure 14. Analysis of the alveolar epithelial lineage phenotype of the miR-142 gain 
of function (GOF) and littermate Control lungs at E18.5. (A) LoxP-Stop-Loxp-miR-142 
knock in mice (in the Rosa26 locus) are crossed with SftpcCreERT2 mice. Cre activation in 
the alveolar epithelial progenitor cells following tamoxifen IP injection to pregnant females 
at E14.5 and E15.5 leads to miR-142 overexpression in these cells. Lungs are analyzed 
then at E18.5. (B) Validation of miR-142-3p and -5p overexpression in E18.5 GOF and 
Control littermate lungs. (C) Flow cytometry analysis of Control and GOF E18.5 lungs for 
AT1 and AT2 cells. (D) Pdpn/Sftpc/DAPI IF staining in E18.5 GOF and Control littermate 
lungs.  (E) AT1 and AT2 gene signature analysis in FACS-isolated AT2 cells from E18.5 




4.10 Loss of miR-142 expression in vitro is sufficient to increase the AT2/AT1 cell 
ratio.  
 
Our results with the use of a constitutive KO for miR-142, leave open the possibility that 
the observed effect on alveologenesis may derive from secondary effects, due to early 
deletion of miR-142 expression. To evaluate the impact of the miR-142 loss of function at 
the time in which AT2 (Sftpc) and AT1 (Pdpn) cell markers arise, we performed in vitro 
treatment with morpholino specific for miR-142-3p and -5p on E14.5 lung explants, and 
cultured them for 4 days (Fig. 15A). This approach allowed to analyze the effect of miR-
142 LOF at a time when early alveolar progenitors have yet to become bipotent progenitors 
for the AT1 and the AT2 cells. We observed a significant decrease in the expression of 
miR-142-3p and -5p respectively (Fig. 15B). Treatment with both morpholinos together 
(mo-(3p+5p)) led to the simultaneous knock-down of both miR-142 isoforms (Fig. 15B). 
The decrease in the expression of these miRNAs were further confirmed by upregulation 
of their respective target genes such as Apc, Ep300, and Kras (Fig. 15C). Interestingly, 
the attenuation of miR-142-3p and/or 5p led to the increase in Sftpc expression while 
decreasing the expression of Pdpn (Fig. 15D). In accordance with our in vivo data, FACS 
analysis of AT2 and AT1 cells in these lungs grown in vitro demonstrated an increase in 
the percentage of AT2 (14.8% ± 1.33% vs. 7.9% ± 4.8% in mo-(3p+5p) vs. Scrambled, 
respectively, p=0.049, n=4) and a decrease in AT1 (0.86% ± 0.2% vs. 2.8%± 1.1% in mo-
(3p+5p) vs. Scrambled, respectively, p=0.01, n=4) (Fig S6A-D). Therefore, our results 
demonstrate that in vitro knockdown of miR-142 recapitulates the in vivo phenotype in 
terms of AT2/AT1 ratio. These results reinforce the concept that the observed phenotype 
is due to a direct effect of perturbing miR-142 signaling, rather than to secondary effects 






Figure 15. In vitro differentiation of the alveolar epithelial progenitors. (A) Schematic 
in vitro treatment of E14.5 WT lung explants with morpholinos specific to miR-142-3p and 
mir-142-5p for 4 days. Impact of morpholino treatment on (B) miR-142-3p and -5p (C) Apc, 
Ep300, Kras (D) Sftpc and Pdpn expression (E) IF staining of Sftpc on E14.5 lung explant 
culture treated with morpholino-miR-142-5p for 4 days. (F) Schematic in vitro culture of 
E14.5 WT lung explants with morpholinos for 4 days in presence of either IQ-1 (10µM) or 
SCH772984 (10µM), (a specific inhibitor of ERK1/2). qPCR analysis (G-I) and IF staining 
(H-J) showing the level of expression of Sftpc on E14.5 lung explant cultures in presence 





4.11 Blockade of Ep300-Ctnnb1 in vitro using the pharmacological inhibitor IQ-1 
prevents morpholino-miR-142-induced increase in Surfactant Protein C 
(Sftpc).  
 
In order to identify the molecular mechanism responsible for the regulation of 
alveolar lineage phenotype by miR-142, we employed the pharmacological 
inhibitor IQ-1 (blocks Ep300-Ctnnb1 interaction) and SCH772984, a specific 
inhibitor of Erk1/2 (inhibits Kras/Erk signaling). Treatment with IQ-1 (10 µm) and 
SCH772984 (10 µm) on E14.5 lung explants for 4 days showed that both inhibitors 
are efficient in reducing Sftpc expression (Fig. 15E, H, J and Fig. S6E, G) but do 
not alter the level of Pdpn expression (Fig. S6F, H). Next, in a rescue experiment, 
we evaluated the impact of these inhibitors in presence of morpholinos against 
miR-142 (Fig. 15F). Silencing miR-142 in IQ-1-treated E14.5 lung explants, led to 
complete downregulation of Sftpc expression indicating that knock down of miR-
142 in this experimental condition, was unable to rescue Sftpc expression (Fig. 
15G, H). On the other hand, silencing miR-142 in SCH772984 (Erk inhibitor) 
treated E14.5 lung explants led to a moderate increase in the expression of Sftpc 
(Fig. 15I, J). These results suggest that Ep300-Ctnnb1 rather than Kras/Erk 
signaling is downstream of miR-142 to control Sftpc expression.





5.1 Validation of miR-142 KO mice 
 
We are among the first group to report the generation and validation of classical miR-142-
KO mice. We showed both isoforms of miR-142, the 3p and 5p, are no longer expressed 
in miR-142-KO mice. The expression of Bzrap1, a gene immediately flanking miR-142, is 
not altered while the expression of a LncRNA embedded within the miR-142 gene is 
abolished. E18.5 miR-142-KO lungs display increased Wnt signaling associated with the 
up-regulation of Apc and Ep300, two previously reported targets of miR-142-3p and -5p, 
respectively. miR-142-KO pups are born alive and are normally represented indicating the 
absence of embryonic lethality. Adult miR-142-KO animals are viable and display impaired 
hematopoietic lineage formation.  
 
A miR-142 gene-trap allele was recently created by insertion of an exogenous gene trap 
sequence 50 bp upstream of the murine pre-miR-142 (Chapnik et al., 2014). In these mice, 
the expression of both 3p and 5p was reduced to very low levels but not completely 
abolished. The authors describe that at E14.5, embryos homozygous for the mutant allele 
display a normal Mendelian distribution. However, one-third of the postnatal homozygous 
mutant mice died within 3 weeks. Our results support these observations with the 
exception of the lack of perinatal death. Even though this remains to be shown, perinatal 
death may be associated with heart failure due to the absence of adaptive growth of the 
cardiomyocytes (Sharma et al., 2012). Similarly, to the homozygous miR-142 gene-trap 
mice, our miR-142-KO mice also display decreased white blood cells, decreased platelets 
and increased mean platelet volume. However, we did not observe the decrease in red 
blood cell numbers as well as the increased level of basophils and reticulocytes (data not 
shown) initially reported in the homozygous miR-142 gene-trap mice. The basis for such 
differences is not known so far and could be linked to the genetic background. 
 
More recently, a conditional KO for miR-142 was generated by deleting 900 bp of the 
genomic sequence that encompasses the miR-142 precursor in the germ line (Kramer et 
al., 2015). The authors reported that miR-142-KO mice are born at the expected 
Mendelian ratio and appear healthy and fertile with no apparent internal organ defects, 
similarly to the findings described in this report. They also described a highly penetrant 
splenomegaly that is also observed in our miR142-KO mice (data not shown). 
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5.2 miR-142-3p and miR-142-5p regulate Wnt signaling by targeting Apc and 
Ep300 respectively. 
 
In order to predict the potential defects observed in miR-142-KO animals, the predicted 
targets for miR-142-3p and 5p were characterized using Diana-MicroT (Vlachos et al., 
2012) and Targetscan (targetscan.org) (Fig S7A). Among the processes and pathways 
potentially affected, we identified endocytosis, regulation of actin cytoskeleton, pathways 
in cancer, TGFb signaling and Wnt signaling. 
 
As the miR-142 conventional KO leads to the deletion of both miR-142-3p and miR-142-
5p, it might be challenging to tease out the activity of each isoform. Others and we have 
previously reported that Apc is a direct target of miR-142-3p. Fig. S7B describes the 
common targets (in orange) for miR-142-3p and 5p as well as unique targets (yellow) for 
each isoform in regard to the Wnt pathway. Reduction in Apc leads to the activation of 
canonical Wnt signaling by preventing the recruitment of Ctnnb1 to the degradation 
complex. Increased Apc expression upon miR-142-3p silencing causes down-regulation 
of Wnt signaling (Carraro et al., 2014; Isobe et al., 2014). On the other hand, Sharma et 
al found that Ep300 is a target of miR-142-5p. A mutual inhibitory loop between Ep300 
and miR-142-5p has also been described and under mechanical stress, Ep300 is 
accumulated in the cardiac cells, which results in the down-regulation of miR-142-5p. The 
loss of miR-142-5p expression activates genes required for myocyte survival and function 
(Sharma et al., 2012). Ep300 is a positive regulator of Ctnnb1, which synergistically 
activates Ctnnb1/TCF transcription (Sun et al., 2000). It is therefore not surprising to find 
that the loss of miR-142 leads to increased expression of both Apc and Ep300 (Fig. 5). As 
Apc is a negative regulator and Ep300 is a positive regulator of Wnt signaling, we expect 
that upon deletion of miR-142, the balance between Apc and Ep300 will lead to either no 
change in Wnt signaling, an increase or a decrease in Wnt signaling. Our analysis of E12.5 
and E18.5 embryonic lungs indicating that the Apc/Ep300 balance favors Wnt signaling. 
The regulation of the relative expression of both isoforms in specific tissues over time is 
still unknown. In the embryonic lung at E18.5, both the -5p and -3p isoforms are normally 
co-expressed in the epithelium and mesenchyme while -3p appears to be more 
abundantly expressed in the mesenchyme at E12.5 (Carraro et al., 2014). In the 
hematopoietic system, -3p is the predominant isoform expressed. In the heart, it appears 
that -5p is the major isoform. Our mouse model allows determining the overall contribution 
of -3p and -5p to Wnt signaling in different tissues and at different developmental stages.  
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5.3 Loss of miR-142 leads to increased AT2/AT1 cell ratio: 
 
The mechanisms regulating alveolar epithelial cells proliferation and differentiation as well 
as the advancement of distinct lung progenitor cells towards given mature alveolar cell 
types are poorly understood (McQualter et al., 2010; Weiss et al., 2008; Zemke et al., 
2009). Recently, studies based on the use of cell-specific markers as well as single cell 
transcriptomic of the epithelium during lung development, have shown that AT1 and AT2 
cells derive from common bipotent progenitor cells (Desai et al., 2014; Treutlein et al., 
2014). 
 
Here, using a constitutive KO mouse model, we report that in the absence of miR-142 
(abolishing both the -3p and -5p strands), there is a relative increase of AT2 and a 
decrease in AT1 cell number (leading to an increase in the AT2/AT1 cell number ratio). 
Supporting a cell-autonomous function for miR-142 in the epithelium, increased miR-142 
from E14.5 to E18.5 in alveolar progenitor cells led to the opposite effect. Interestingly, no 
changes in the number of Epcam or Ki-67 positive cells were observed suggesting a direct 
impact of miR-142 in epithelial cell differentiation. Examination of the KO versus Control 
lungs at E18.5 revealed enhanced expression of the miR-142 targets Apc and Ep300, 
associated with increased Ctnnb1 and pERK signaling. Morpholino-based knockdown of 
miR-142 was sufficient to induce Sftpc, decrease Pdpn, and increase AT2/AT1 cell number 
ratio, as well as Apc, Ep300, and Kras expression. Pharmacological inhibition of Ep300-
Ctnnb1 but not the Kras/Erk signaling completely prevented miR-142 morpholino-based 
increase in Sftpc expression. Activation of the glucocorticoid pathway in an in vitro alveolar 
epithelial lineage differentiation assay was sufficient to achieve decreased miR-142 
expression, and recapitulated the increase of Sftpc expression. These results suggest that 
a novel glucocorticoid-miR-142-Ep300 signaling axis controls the differentiation of alveolar 
progenitors and maintains the balance between the AT1 and the AT2 cell number (Fig.16 
Graphical abstract). 
 
A surprising result was that the increase in AT2/AT1 cell number ratio observed in miR-
142 loss of function is associated with the AT2 cells with a global decrease in the AT2 and 
increased in the AT1 gene profile signature. We hypothesize the existence of a dynamic 
sensing mechanism during lung development, able to detect any unbalance of the 
AT2/AT1 cell number ratio. This sensing mechanism would take advantage of the plasticity 
displayed by the AT2 cells that by responding to uncharacterized compensatory 
mechanisms would prime them for differentiation towards the AT1 lineage. Interestingly, 
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during homeostasis, the AT2 cells are capable of self-renewal but do not normally give 
rise to the AT1 cells. However, in vitro assays with isolated AT2 cells, co-cultured in 
Matrigel with stromal cells, leads to the formation of alveolospheres containing both the 
AT2 and AT1 cells (Barkauskas et al., 2013). Conversely, the AT1 cells appear to be 
mostly terminally differentiated postnatally but can be reactivated, in the context of lung 
regeneration induced by pneumonectomy, to proliferate and give rise to the AT2 cells (Jain 
et al., 2015). It is therefore interesting that this plasticity displayed by alveolar cells 
postnatally can have a similar impact during embryonic lung development. 
 
Etv5 has been recently reported to be important for the maintenance and differentiation of 
the AT2 cells. Conditional deletion of Etv5 postnatally, in the differentiated AT2 cells, leads 
to the decrease in the AT2 and increase in the AT1 signature (Zhang et al., 2017). While 
globally, Etv5 was unchanged in KO vs. control lungs, our gene array analysis showed 
decreased Etv5 expression in miR-142 KO AT2 cells, supporting the loss of AT2 signature 
in these cells (Fig. 5D). Recently, we showed that Fgf10 might represent a crucial 
molecule, controlling the differentiation of the bipotent progenitor cells towards the AT2 
lineage (Chao et al., 2017). Using Fgf10 heterozygous (Fgf10+/-) lungs, we demonstrated 
a decrease in the AT2/AT1 cell ratio. Furthermore, a defect in epithelial differentiation and 
proliferation was observed in Fgf10 hypomorphic lungs showing impairment in the AT2 
lineages (Ramasamy et al., 2007). Etv5 is a known downstream target of Fgf10, and while 
we cannot exclude changes in a component of Fgf10 signaling, Fgf10 per se was 
unchanged in our model. Furthermore, the fact that pharmacological inhibition of Ep300-
Ctnnb1 but not the Kras/Erk signaling completely prevented miR-142 morpholino-based 
increase in Sftpc expression, suggest a prominent role for Wnt signaling.  
 
Recently, a role for histone deacetylase 3 (Hdac3) in the spreading of the AT1 cells and 
lung sacculation was reported. It was shown that Hdac3 expressed in alveolar progenitors 
represses the expression of miR-17-92 (Wang et al., 2016b). miR-142 does not appear to 
impact the spreading of the AT1 cells as no such defects were detected at E18.5 or 
postnatally (data not shown). In addition, the adult KO lungs are functional and appear 
histologically normal ((Shrestha et al., 2015) and data not shown). There is no evidence 
so far of an organized cross talk between miR-142 and miR-17-92 during the late phase 
of lung development. During early development miR-17-92 was shown to modulate Fgf10-
Fgfr2b signaling by specifically targeting Stat3 and Mapk14, hence regulating Cdh1 
expression. The Cdh1 expression level, in-turn, fine-tunes Ctnnb1 signaling in the 
epithelium, which is critical for epithelial bud morphogenesis triggered by Fgf10 (Carraro 
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et al., 2009). Interestingly, mutant lungs with specific deletion of Hdac3 in the mesenchyme 
also display impairment of the AT1 differentiation, correlating with decreased Ctnnb1 
signaling in the epithelium. Rescue of Ctnnb1 signaling in the mutant lung partially rescues 
the AT1 cell differentiation defects (Wang et al., 2016a). Again, as Ctnnb1 signaling is 
increased in the miR-142 KO epithelium, it is very unlikely that this leads to the perturbation 
of the AT1 differentiation, the conclusion that is supported by our analysis. 
 
5.4 Glucocorticoids-miR-142-Ep300 signaling axis controls the alveolar 
epithelial lineage formation 
 
To identify the molecular mechanism involved in the regulation of alveolar epithelial 
phenotype by miR-142, we employed a well-established model to activate glucocorticoid 
signaling using dexamethasone to stimulate the maturation of alveolar cells into functional 
AT1 and AT2 cells (Alanis et al., 2014; Laresgoiti et al., 2016). Interestingly, we noted a 
reduced expression of miR-142-3p and miR-142-5p in lung explants treated with 
glucocorticoid agonists, suggesting that the reduced level of miR-142 is required for the 
differential of alveolar epithelial cells. Furthermore, we demonstrated two equally important 
pathways downstream of miR-142 playing an important role in the formation of the alveolar 
lineage. Ep300/Ctnnb1 interaction has been shown to be one of the pathways involved in 
the differentiation of adult epithelial progenitors (Rieger et al., 2016) as well as 
differentiation of embryonic stem cells and regulation of proximal-distal axis during lung 
development (Sasaki and Kahn, 2014). Apc and Ep300, two critical targets of miR-142, 
can control Ctnnb1 pathway. Apc is part of the degradation complex for Ctnnb1 and is, 
therefore, a negative regulator of Ctnnb1 signaling. Conversely, Ep300 binds to Ctnnb1 
and acts as a co-transcriptional activator.  In vitro blockade of Ctnn1/Ep300 interaction 
with the use of IQ-1 showed complete down-regulation of Sftpc expression, suggesting 
impairment in the alveolar epithelial lineage, while miR-142 LOF was unable to rescue the 
expression of the AT2 marker (Fig 7H). The other pathway controlled by miR-142 is the 
Kras/Erk pathway. A recent report indicated that miR-142 is highly expressed in 
undifferentiated mouse embryonic stem cells (mESCs) and downregulated in differentiated 
cells. It was also reported that overexpression of miR-142 interrupted mESCS 
differentiation. A double-negative feedback loop between Kras/Erk and miR-142 levels has 
been suggested. Low level of miR-142 triggers Kras and Erk phosphorylation, which in 
turn induces mESC differentiation and vice-versa (Sladitschek and Neveu, 2015). 
However, evidence suggests that Kras represses the formation of the alveolar lineage as 
forced activation of Kras in the distal lung epithelium in vivo suppresses the alveolar 
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differentiation program (Chang et al., 2013). In our in vitro model, lung explants treated 
with Erk inhibitor alone showed reduced Sftpc expression whereas Erk inhibitor treatment 
in combination with morpholino specific to miR-142 showed a moderate increase in the 
Sftpc expression indicating a mild rescue in the alveolar lineage phenotype (Fig. 7J).  
 
In conclusion, we report for the first time, an important role played by both isoforms of miR-
142 in alveolar epithelial lineage formation. We show that miR-142 governs the formation 
of AT1 progenitors thereby controlling the AT2/AT1 cell ratio. We propose that a 
glucocorticoid-miR-142-Ep300 signaling axis controls alveolar epithelial lineage formation. 
 
5.5. Future Perspective 
 
Increased Wnt signaling has been observed in hyper proliferative diseases like Idiopathic 
pulmonary fibrosis (IPF), a fatal lung disease, which is characterized by, increased 
fibroblast proliferation, the presence of fibroblastic foci, honeycombing in lung and alveolar 
tissue remodeling leading to respiratory failure (Morrisey, 2003). On the other hand, 
increased expression of miR-142-5p has been seen in the macrophages of the patients 
with liver cirrhosis and idiopathic pulmonary fibrosis (Su et al., 2015). 
 
In addition to this, a loss of normal alveolar architecture accompanied the loss of AT1 and 
AT2 cell balance and fibrotic remodeling was observed in IPF samples (Desai et al., 2014). 
Since we have demonstrated that miR-142 can regulate the differentiation of alveolar 
epithelial cells during lung development we propose that miR-142 can play a functional 
role in Idiopathic pulmonary fibrosis (IPF).  
 
Therefore, our future goal is to understand the regulatory mechanism of miR-142 in 
pulmonary fibrosis. If we could provide the molecular mechanism that mediates or 
regulates pulmonary via miR-142, it would be a one step closer to develop a therapeutic 
approach to reduce the severity of IPF. 
 
Furthermore, microarray studies performed on the mouse lung infected with 2009 
Pandemic H1N1 influenza A virus showed differential expression pattern of miR-142-3p 
(Wu et al., 2013). 
 
Additionally, other studies demonstrated that insertion of miR-142 target site into the 
nucleoprotein of influenza A virus (IAV) attenuates the virus replication (Langlois et al., 
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2012). Considering all these data, we consider that our miR-142 KO mice must be more 
susceptible to influenza A virus infection.  
 
As influenza A virus mostly infects the epithelial cells of the upper and lower respiratory 
tract contributing from mild infection to more severe pneumonia associated with acute 
respiratory distress syndrome. It would be quite interesting to understand the link between 
miR-142 and influenza virus infection that will be beneficial for the prevention and control 
of influenza A virus infection. 
 
miR-142 has been shown to be linked with various cancers including lung adenocarcinoma 
(Kaduthanam et al., 2013).Others and our own initial studies demonstrated that miR-142 
is significantly expressed in the mouse model of Bronchopulmonary Dysplasia (BPD), a 
chronic lung disease affecting mostly premature infants (Nardiello and Morty, 2016; Xing 
et al., 2015). Better in-depth studies need to be performed in future to understand the 





6. Summary  
 
microRNA-142 (miR-142) is emerging as a major regulator of cell fate decision in the 
hematopoietic cell lineages (Chen et al., 2004) as well as in the maintenance of 
pluripotency of embryonic stem cells (Sladitschek and Neveu, 2015). However, miR-142 
is also expressed in many other tissues and evidence suggests that it may play a more 
pleiotropic role during embryonic development and disease. Therefore miR-142 is 
regarded as an important regulator of many biological processes and associated signaling 
pathways during embryonic development, homeostasis, and disease.  
 
The miR-142 hairpin gives rise to the miR-142-3p and miR-142-5p. Both variants of miR-
142 are functional and can act on different independent target genes. Previously, we 
reported that miR-142-3p was critical for the control of Wnt signaling in the mesenchyme 
during lung development (Carraro et al., 2014). miR-142-5p has shown to control adaptive 
growth in the cardiomyocytes postnatally and its increase is associated with extensive 
apoptosis and cardiac dysfunction. (Sharma et al., 2012).  
 
To understand the role of miR-142 in vivo, we generated miR-142 KO mice using 
homologous recombination. Our validation studies showed that 
 
• These mice showed significant decrease in both the 3p and 5p isoforms with 
impaired hematopoietic lineage formation, identical to previously reported miR-142 
gene trap knockdown mice (Chapnik et al., 2014).  
• The expression of Bzrap1, a gene immediately flanking miR-142 is not altered while 
the expression of a long non-coding RNA embedded within the miR-142 gene is 
decreased.  
• miR-142 KO pups are born alive and are normally represented indicating absence 
of embryonic lethality. 
• miR-142 KO lungs display increased Wnt signaling associated with the up-
regulation of Apc and Ep300, two previously reported targets of miR-142-3p and -
5p, respectively 
We further explored the significant role of miR-142 in alveolar epithelial lineage formation 
during embryonic lung development. Squamous alveolar type 1 (AT1) and cuboidal 
alveolar type 2 (AT2) cells lining the alveolar sacs are regarded among the most important 




as well as through surfactant production. These AT1 and AT2 cells are derived from 
bipotent epithelial progenitor cells (Desai et al., 2014; Treutlein et al., 2014). In spite many 
studies, very little is known about the alveolar progenitor cells regulating the formation 
maturation and maintenance of AT1 and AT2 cells. Furthermore, the roles of specific 
microRNAs on these cells are poorly understood. Our analyses demonstrate that  
 
•  miR-142 is expressed in the bipotent progenitors as well as in the differentiated 
AT1 and AT2 cells.  
• miR-142 is expressed at the much higher level in differentiated AT1 compared to 
AT2 cells suggesting a specific function for this miR in the formation of the AT1. 
• We further demonstrate a significant decrease of AT1 and a corresponding 
increase of AT2 cells in the lungs of miR-142 KO embryos. 
• Increase in AT1 and the corresponding decrease in AT2 cell number is observed 
in a mouse model allowing over-expression of miR-142 in alveolar epithelial 
progenitors. Such changes occur in absence of alterations at the level of epithelial 
proliferation or number of bipotent cells. 
 
In an in vitro model for alveolar epithelial lineage differentiation assay using 
dexamethasone (Laresgoiti et al., 2016), we demonstrate that 
 
• Activation of the glucocorticoid pathway led to increased expression of the AT2 
marker Sftpc and decreased miR-142 expression. 
• Ep300-Ctnnb1 signaling and Kras/Erk signaling pathway are proposed to be two 
major pathways involved in the regulation of alveolar differentiation (Rieger et al., 
2016; Sasaki and Kahn, 2014; Sladitschek and Neveu, 2015). Pharmacological 
inhibition of Ep300-Ctnnb1 but not the Kras/Erk signaling completely prevented 
miR-142 morpholino-based increase in Sftpc expression.  	
These results therefore suggest that a critical glucocorticoid-miR-142-Ep300 signaling axis 







Figure 16. Graphical abstract: A glucocorticoid-miR-142-Ep300 signaling axis 
controls the formation of the alveolar epithelial lineage. Glucocorticoids (GC) are 
enhancing AT1 and AT2 formation. GC inhibits miR-142 expression. Inhibition of miR-142 
is sufficient to increase the AT2 to AT1 ratio but does not perturb the flattening of the AT1 
cells. We propose that miR-142 negatively regulates bipotent cells (BP) to AT2 
differentiation while it enhances BP to AT1 differentiation. In addition, GC can also act 




7.  Zusammenfassung 
 
Die microRNA-142 (miR-142) ist ein wichtiger Regulator der hämatopoetischen Zelllinie 
(Chen et al., 2004) und spielt eine Rolle beim Erhalt der Pluripotenz embryonaler 
Stammzellen (Sladitschek and Neveu, 2015). 
 
MiR-142 wird aber auch in anderen Geweben exprimiert; es gibt Hinweise, dass sie eine 
weitreichende pleiotrope Rolle in der Embryonalentwicklung und bei der Entstehung von 
Erkrankungen spielt. MiR-142 gilt daher als ein wichtiger Regulator vieler biologischer 
Prozesse und die damit assoziierten Signalwege während der Embryonalentwicklung, der 
Homöostase sowie bei Erkrankungen.  
 
Die miR-142 kommt als miR-142-3p und miR-142-5p vor. Beide Varianten sind funktional 
und wirken unabhängig auf verschiedene Zielgene. 
Bisher konnten wir zeigen, dass miR-142-3p während der Lungenentwicklung den Wnt-
Signalweg im Mesenchym kontrolliert (Carraro et al., 2014). Die miR-142-5p steuert das 
postnatale, adaptive Wachstum der Kardiomyozyten; ein Anstieg der miR-142-5p steht in 
Zusammenhang mit einer vermehrten Apoptose und kardialen Dysfunktion (Sharma et al., 
2012). 
Zum besseren Verständnis der Rolle von miR-142 in vivo wurde mit Hilfe homologer 
Rekombination eine miR-142 KO Maus generiert.  
Die Validierungsstudien ergaben folgende Resultate:  
• Diese Mäuse weisen einen signifikanten Abfall der 3p und 5p Isoformen mit einer 
gestörten Entwicklung der hämatopoetischen Zelllinie. Gleiche Ergebnisse wurden 
zuvor auch bei der miR-142 Gene Trap Knockdown Maus gezeigt (Chapnik et al., 
2014). 
• Die Expression von Bzrap1, eines Gens, welches das miR-142 Gen unmittelbar 
flankiert, ist unverändert. Die Expression einer im miR-142 Gen eingebetteten non-
coding RNA ist jedoch vermindert.  
• Es konnten festgestellt werden. Die miR-142-KO Mäuse werden lebend geboren 
und zeigen keine Anzeichen für embryonale Sterblichkeit .  
• miR-142-KO Lungen zeigen ein erhöhtes Wnt-Signalweg, welches mit einer 
Hochregulation von Apc und Ep300 assoziiert ist. Apc und Ep300 wurden bereits 





Weiterhin wurde der Einfluss von miR-142 auf die Entwicklung der alveolaren 
Epithelzelllinie während der embryonalen Lungenentwicklung untersucht. Die alveolaren 
Zellen vom Typ I (AT1) und vom Typ II (AT2) kleiden die Alveolen aus und gelten als die 
wichtigsten Zellen der Lunge, da sie den Gasaustausch ermöglichen und Surfactant 
produzieren. Die AT1 und AT2 Zellen entwickeln sich aus bipotenten epithelialen 
Vorläuferzellen (Desai et al., 2014; Treutlein et al., 2014). Trotz zahlreicher Studien, ist 
wenig über die Bildung, die Reifung und den Erhalt der AT1 und AT2 Zellen durch die 
alveloaren Vorläuferzellen bekannt. Weiterhin ist die Bedeutung spezifischer microRNAs 
kaum untersucht.  
Aus unseren Untersuchungen konnten wir ableiten:  
• miR-142 wird in den bipotenten Vorläuferzellen und in den differenzierten AT1 und 
AT2 Zellen exprimiert.  
• Eine stärkere Expression von miR-142 in den differenzierten AT1 Zellen  als in den 
differenzierten AT2 Zellen weist auf eine spezifische Funktion der miR-142 bei der 
Bildung der AT1 Zellen hin.  
• Wir konnten eine signifikante Reduktion von AT1 und einen entsprechenden 
Anstieg von AT2 Zellen in den Lungen von miR-142-KO Embryonen zeigen. 
• Im Mausmodell der induzierbaren Überexpression von miR-142 in alveolaren 
epithelialen Vorläuferzellen beobachteten wir einen Anstieg von AT1 Zellen und 
einen entsprechenden Abfall von AT2 Zellen. Dabei konnten keine Veränderungen 
der epithelialen Proliferation oder der Anzahl der bipotenten Zellen festgestellt 
werden.  
 
In einem in-vitro Modell zur Differenzierung der alveolaren epithelialen Zelllinie mit 
Dexamethason konnten wir folgendes zeigen (Laresgoiti et al., 2016):  
• Eine Aktivierung des Glukokortikoid Signalweg führt zu einer erhöhten Expression 
des AT2 Markers Sftpc und eine verminderten Expression von miR-142. 
• Die Ep300-Ctnnb1 und Kras/Erk Signalwege gelten als zwei wichtige Signalwege 
zur Regulation der alveolaren Differenzierung (Rieger et al., 2016; Sasaki und 
Kahn, 2014; Sladitschek und Neveu, 2015). Die pharmakologische Inhibition des 
Ep300-Ctnnb1, aber nicht des Kras/Erk Signalweges, verhindert die durch 
Morpholino gegen miR-142 induzierte erhöhte Expression von Sftpc.  
Diese Ergebnisse deuten darauf hin, dass die Glukokortikoid-miR-142-Ep300 Signalachse 







Fig. 16: Graphische Darstellung: Eine Glukokortikoid-miR-142-Ep300 Signalachse 
steuert die alveolare Epithelzelllinie: Glukokortioide (GC) verstärken die AT1 und AT2 
Bildung. GC hemmen die miR-142 Expression. Diese Hemmung ist ausreichend, das 
Verhältnis von AT2 zu AT1 zu erhöhen, ohne die Streckung der AT1 zu stören. Wir gehen 
davon aus, dass miR-142 ein negativer Regulator der Differenzierung von bipotenten 
Zellen (BP) zu AT2 Zellen ist, während es die Differenzierung von BP zu AT1 verstärkt. 
Darüber hinaus können Glukokortikoide - unabhängig von miR-142 - die Differenzierung 
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9. Supplementary Material 
 
		 	 	 	 	 	 	 	 	
Figure S1. FACS-based isolation of resident epithelial and mesenchymal cells and 
validation of gene expression. (A) FACS-based isolation of CD31-ve CD45-ve Epcam+ve 
(resident epithelium) and Epcam-ve (resident mesenchyme). Quantification showing the 
epithelial to mesenchymal ratio at E14.5 and E18.5. (B) qPCR validation of the isolated 
epithelial and mesenchymal cells using epithelial (Cdh1, Epcam, Fgfr2b) and 
mesenchymal (Fgf10, Acta2, Vimentin) markers at these two time points. (C) Expression 
analysis of miR-142 targets Apc, Ep300, gp130 and Kras in the mesenchyme as well as 
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Figure S2. Gene Array and KEGG pathway analysis on E12.5 and E18.5 Control and 
KO lungs. A) Gene expression analysis of miR-142 target genes by qPCR in E12.5 and 
B) E18.5 Control and miR-142 KO lungs C) Gene array analysis (n=3). D) Corresponding 





Figure S3. Quantification of the number of Epcam as well as AT2 cells in Control 
and Experimental miR-142 KO lungs at E18.5. Analysis of proliferation (A) Flow 
cytometric analysis using Epcam and Sftpc antibodies in E18.5 miR-142 KO showed an 
increase in the percentage of AT2 cells compared to the wild type littermate controls. (B) 
Flow cytometry analysis using Epcam, Sftpc and Pdpn antibodies in E18.5 miR-142 KO 
lungs showed a decrease in Pdpn+ve (AT1)  and increased in Sftpc +ve (AT2) cells 
compared to the wild type littermate controls. Quantification of Pdpn+ve and Sftpc +ve 
cells. (C) qPCR analysis for general epithelial markers (Cdh1, Epcam) as well as for 
markers of the conducting (p63, Scgb1a1) and respiratory (Sftpc, Pdpn) airways. (D) 
Cdh1/Ki67 double IF staining in E18.5 Control and KO lungs showed no significant 







Figure S4. Examination of Fgf signaling in E18.5 miR-142 Control and KO lungs. (A) 
qPCR analysis of Fgf10, Fgfr1b, Fgfr2b Fgfr2c, Sprouty2 and Etv5 in E18.5 Control and 
KO lungs. (B) Fgfr2 expression in the epithelium is validated by immunofluorescence with 
Fgfr2 and Cdh1 antibodies. Quantification indicating increased number of Fgfr2+ve cells in 





Figure S5. High magnification of the heatmaps shown in Figure 3 and 5. (A-C) Gene 
array analysis on FACS-isolated AT2 cells from E18.5 Controls and miR-142 KO mice 
(n=4). (D-F) Gene array analysis on FACS-isolated AT2 cells from E18.5 Controls and 






Figure S6. In vitro alveolar epithelial lineage formation. Flow cytometry analysis on the 
number of Epcam (A), bipotent (B), AT2 (C) and AT1 (D) cells in lungs cultured with 
morpholino miR-142-3p and -5p (mo-(3p +5p)) together. Expression of Sftpc and Pdpn 
upon IQ-1 treatment (E, F) or Erk inhibitor (G, H) treatment in E14.5 lungs grown in vitro 












Figure S7. Predicted targets of miR-142-3p and miR-142-5p using Diana-MicroT and 
Target Scan software prediction tools. (A) Pathway intersection between miR-142-3p 
and miR-142-5p.  (B) Predicted targets of miR-142-3p and miR-142-5p in the Wnt 
signaling pathway. Orange boxes: common predicted targets for both isoforms; yellow 
boxes: predicted targets for both isoforms; green boxes: experimentally validated target 
of miR-142-3p; red box: experimentally validated targets for miR-142-5p. 
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